Use of recombinant antigen in the diagnosis of Crimean-Congo haemorrhagic fever virus infection by Seleka, G. P.
Use of recombinant antigen in the diagnosis of Crimean-Congo 
haemorrhagic fever virus infection
GOPOLANG PATRICK SELEKA
A dissertation submitted to the Faculty of Health Sciences 
University of the Witwatersrand, Johannesburg 
For the degree o f Master of Science 
Johannesburg 2001
Declaration
I declare that this dissertation: Use o f recombinant antigen in the diagnosis o f Crimean-Congo 
haemorrhagic fever virus infection, is my own work. It is being submitted to the University of the 
Witwatersrand, Johannesburg, for the degree Master of Science. It has not previously been submitted
for any degree or examination at this or any other University.
//
Gopolang Patrick Seleka
SO^~on this day of ,2002
1
Abstract
The Special Pathogens Unit (SPU) of the National Institute for Virology has diagnosed a total of 158 
cases of Crimean-Congo haemorrhagic fever (CCHF) from the time that the disease was first 
recognized in South Africa in 1981 up until the end of 2000. The virus has a propensity to cause 
nosocomial infections, and consequently rapid diagnosis is important for the isolation o f the patient 
and the institution o f barrier-nursing to protect medical staff and the community at large. Thus it is 
essential that the SPU should have the latest diagnostic and research tools available.
Diagnosis of CCHF is generally confirmed by isolation of the virus, detection o f viral RNA 
amplified by reverse transcriptase polymerase chain reaction (RT-PCR), demonstration of 
seroconversion or a >4-fold increase in IgG antibody titre, or detection o f specific IgM antibody 
activity. Virus can be isolated in 1-6 days in cell culture, but the method is less sensitive for the 
isolation o f low concentrations of virus than the use of suckling mice which, however, takes 7-9 
days. Enzyme-linked immunosorbent assay (ELISA) and indirect immunoflourescence (IF) antibody 
tests are the most useful for serological diagnosis of CCHF in humans because these tests can 
distinguish between IgG and IgM in order to confirm that infection has been recent, and to establish 
that antibody activity detected in the sera of patients does not result merely from the use of immune 
plasma therapy. However, one of the problems of diagnosing viral haemorrhagic fevers is the 
biohazardous nature o f the test reagents which require biosafety level 4 (BSL4) facilities for 
preparation and use. Reagents must be inactivated and safety tested before they can be used in other 
laboratories. A further requirement for safe antigen arises from the need to screen livestock sera for 
antibody to CCHF virus as a prerequisite to the export o f live animals, and in this respect the export 
of ostriches from southern Africa to Europe has created a particular demand in recent years.
Recombinant antigens are being used more frequently as diagnostic reagents in virology and have 
the advantage that they are non-hazardous. Because the SPU has a unique collection o f sera derived 
from confirmed CCHF patients and from experimentally infected animals, it was asked to test 
candidate recombinant CCHF reagents which had been prepared by BSL4 laboratories abroad. The
u
reagents comprised a baculovirus recombinant expressing CCHF nucleocapsid protein received from 
one laboratory, plus three recombinant nucleoprotein antigens from another. The initial purpose of 
the present study, therefore, was to evaluate the reagents received from abroad, but in case none of 
them proved to be satisfactory it was decided to attempt the production of further recombinant 
antigen at the same time.
The recombinant baculovirus produced for the present project failed to express antigenically active 
nucleoprotein, and the 3 recombinant proteins received from a laboratory abroad were weakly 
reactive and could not be tested as diagnostic antigens. However, the recombinant baculovirus 
received from the other laboratory abroad expressed antigenically active CCHF nucleocapsid protein, 
and this produced promising results in IgM and IgG ELISA on 135 serum samples from confirmed 
human CCHF patients and on 63 sera from experimentally infected sheep, as well as in competitive 
ELISA (CELISA) on the 135 human sera and on 35 samples from experimentally infected small 
mammals, plus 271 samples from ostriches. In the various tests on the sera of the different species 
the sensitivity of the results produced by the recombinant antigen ranged from 82.1-100% in 
comparison with the sensitivity of the reference antigen prepared by sucrose acetone extraction of 
infected mouse brain, while the specificity o f the results produced by recombinant antigen ranged 
from 53.3-100%. It appears likely that the sensitivity and specificity o f the recombinant antigen can 
be improved to be comparable to those of the sucrose acetone antigen relatively easily by adjusting 
the cut off values of the reactions for positivity. However, this will need to be based on prospective 
studies on serum samples received at the SPU for the investigation o f suspected CCHF since 
definitive determinations o f sensitivity and specificity should ideally be conducted in the context of 
the syndrome under investigation, and not in comparison with random samples from general 
populations such as blood donors. Nevertheless, the present results based on selected positive and 
negative sera provide strong evidence in support o f proceeding with prospective studies on the 
recombinant antigen.
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1.0. Introduction and review of literature
1.1. History
In 1944 over two hundred cases of acute febrile illness accompanied by severe bleeding 
manifestation occurred in Russian troops and peasants who were harvesting crops in war devastated 
Crimea. The disease was given the name Crimean haemorrhagic fever (CHF) (Hoogstraal, 1979) and 
in the following year, 1945, Russian scientists showed by inoculation of volunteers that the disease 
was caused by a filterable agent present in blood collected from patients during the acute phase of 
illness, and that the agent was also present in ticks. In 1969, the use o f suckling mice made it 
possible to isolate and characterize the virus, and it was shown to be antigenically identical to an 
African virus, Congo virus, isolated in 1956 from the blood of a febrile patient in what is now the 
Democratic Republic of the Congo (Simpson et al, 1967; Casals, 1969; Casals and Tignor, 1974; 
Chumakov et al, 1970). It was confirmed by Donets et al. (1977) that CHF and Congo viruses have 
the same physiochemical characteristics. Since the viruses were identical, the use of Crimean 
haemorrhagic fever-Congo (CHF-C) virus was suggested as a common name (Casals and Tignor, 
1974). Even although some Russian writers use only CHF and those working with the virus in Africa 
prefer the name Congo, the virus is generally known as Crimean-Congo haemorrhagic fever (CCHF) 
virus.
The first case o f CCHF virus infection to be confirmed in South Africa was recorded when the virus 
was isolated from the blood o f a 13 year old boy who died in a haemorrhagic state in Johannesburg 
on 19 February 1981 (Gear, et al, 1982; Swanepoel et a l, 1983a). To date a total o f 158 cases of 
CCHF with 37 fatalities have been confirmed in southern Africa (unpublished laboratory records).
1.2. The Virus
CCHF virus is a member of the family Bunyaviridae, genus Nairovirus (Casals and Tignor, 1980; 
Matthews, 1982). Nairoviruses have properties similar to other members of the Bunyaviridae in that 
they are spherical structures 90-120 nm in diameter, with host derived envelope incorporating virus 
coded glycoprotein (G) surface projections (Donets, et al., 1977; Ellis et al, 1981). The genome
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consists of three segments o f negative sense, single stranded RNA designated small (S), medium (M) 
and large (L) with the approximate sizes L: 4.1-4.9 X106daltons, M: 1.5-1.9X106 daltons and S: 0.6- 
0.7X106 daltons.(Bishop, et al., 1980; Clerx et al., 1981). The first 8-13 nucleotide bases at the 3 end 
of the RNA segments tend to have a sequence which is conserved within the viruses of the genus, 
with a complementary consensus sequence occurring at the 5 end. The ends of the segments are 
covalently linked so that the RNA occurs in a loosely bound circular configuration within the 
nucleocapsid. The segmented nature o f the genome suggests that the potential exists for reassortment 
to occur in co-infection, although this has never been recorded (Swanepoel, 1994). The M segment 
codes for the viral glycoproteins, G1 and G2, which are believed to be responsible for recognition 
of receptor sites on susceptible cells, manifestation o f viral hemagglutinating ability and induction 
o f a protective immune response in the host (Clerx et al., 1981). The S segment codes for the 
nucleocapsid protein (N). The N protein has a net positive charge and induces production of, and 
reacts with, complement fixing antibodies (Clerx et al., 1981; Marriott and Nuttall, 1992). The L 
segment is believed to code for the viral transcriptase (Elliot, 1990).
CCHF virus is highly labile, very sensitive to the effects of lipid solvents and is inactivated by ether, 
chloroform and ultraviolet light (Bishop, et al., 1980; Smirnova, 1979). The virus is infective in a 
limited pH range o f 6.0-9.5, and has half-life of 2-3 h at 37° C, 10-20 min at 45° C and less than 1 
min at 56° C. Ultraviolet radiation inactivates 99% of infectivity in 1 min and within 3 min the virus 
loses all infectivity (Donets et al., 1977).
1.3. Antigenic relationships
The Bunyaviridae is composed of 4 recognised genera of animal viruses, Bunyavirus, Nairovirus, 
Phlebovirus and Hantavirus plus a genus of plant viruses (Bishop et al., 1980, Murphy et al., 1995). 
The Nairovirus genus is composed of seven antigenic serogroups, and CCHF virus belongs to a 
serogroup of the same name. There are two other member of the CCHF serogroup, Hazara and 
Khasan, neither of which have been shown to be pathogenic for humans. Other members o f the 
genus known to be pathogenic for human are Nairobi sheep disease and Dugbe viruses (Clerx, et al., 
1981; Watts et al., 1989). Nairobi sheep disease virus o f East Africa is believed to be identical to
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Ganjam of India, and is a tick borne pathogen of sheep and goats which causes benign illness in 
humans. Dugbe is a tick borne virus which is commonly associated with infection o f cattle and sheep 
in West Africa, and causes benign disease in human (Swanepoel, 1994). Hazara virus is most closely 
related antigenically to CCHF virus as shown by haemagglutination inhibition (HAI), complement 
fixation (CF) and indirect immunofluorescence (IF) techniques. Even although members of the 
Nairobi sheep disease serogroup are related to the CCHF serogroup they show weak HAI, IF and CF 
cross-reactions (Casals and Tignor, 1980). Marriott and Nuttall (1992) showed that the genetic 
sequences of the N proteins o f CCHF and Hazara viruses are more closely related to each other (60% 
amino acid identity) than to the N protein of Dugbe (55.4% identity with CCHF, and 53.0% identity 
with Hazara), and 39.5% amino acids are conserved across all three viruses. Both CCHF and Hazara 
N protein genes are larger than that of Dugbe virus, having extra sequences at their carboxyl termini.
1.4. Replication
Replication strategies of CCHF virus are still unknown (Bishop et al., 1980) and the early events in 
the infection process of members o f the family Bunyaviridae are not well defined. Like other 
enveloped viruses, one or both integral viral envelope proteins mediate attachment to host cell 
receptors. The main stages of CCHF virus morphogenesis include assembly of virion on the 
membrane of the Golgi complex, transportation of virus containing vacuoles to the cell surface and 
virus release by exocytosis. It seems that the final differentiation of the virion envelope occurs after 
budding as the vacuole moves to the surface. Virus release from the cell may also occur upon lysis 
of the infected cell (Donets, et al., 1977; Elliot et al., 1990).
1.5. Distribution
CCHF virus is widely distributed in Asia, eastern Europe and Africa (Hoogstraal, 1979). The list of 
countries where the virus or the antibody is known to occur has grown over the past four decades, 
probably due to an increased awareness rather than the spread of the infection to new areas. The 
strongest evidence to support this conclusion relates to the coincidence in distribution o f the virus 
and its main vectors, ticks o f the genus Hyalomma (Swanepoel et al., 1987). Human cases have been 
reported in Bulgaria, Burkina Faso, Greece, Iraq, Mauritania, Namibia, Oman, Pakistan, South
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Africa, Tanzania, Yugoslavia, Uganda and United Arab Emirates (Hoogstraal, 1979; Antoniadis, et 
al., 1982; Butenko and Chumakov, 1990; Burney, et al., 1980; Chumakov et al. ,1970; Gear, et al., 
1982; Hoogstraal, 1979; Saluzzo, etal., 1985; Schwartz, etal., 1995; Scrimgeour, 1996; Simpson, 
etal., 1967; Suleiman, 1980; Swanepoel etal., 1983a; Swanepoel etal., 1987). The virus has been 
isolated from ticks and non-human mammals in Ethiopia, Greece, Kenya, Madagascar, Nigeria and 
Senegal, (Camicas, etal., 1990; Causey, etal., 1969; Hoogstraal, 1979; Morrill etal., 1991; Wood 
et al., 1978). Furthermore, serological evidence o f the presence o f the virus has been reported from 
Afghanistan, Egypt, Hungary, India, Iran, Turkey and Portugal (Hoogstraal, 1979; Morrill et al., 
1990; Saidi etal., 1975).
1.6. Vectors
The virus has been isolated from 31 species of ticks which include 2 argasids and 29 ixodids (11 
Hyalomma, 9 Rhipicephalus, 4 Boophilus, 2 Dermacentor, 1 Amblyomma, 1 Haemaphysalis and 1 
Ixodes), although very few species have been proved experimentally to be capable of transmitting 
infection (Camicas et al., 1990; Hoogstraal, 1979; Shepherd et al., 1989a; Watts et al., 1989).
1.7. Transmission
1.7.1. Transmission to humans
Like most of the arthropod-borne agents causing human disease, CCHF virus is generally a zoonosis 
circulating unnoticed in nature in a tick and non-human vertebrate cycle (Hoogstraal, 1979). A 
common mode of transmission of CCHF virus to humans is by tick-bite, as in the first confirmed 
case in South Africa; but humans also acquire infection from crushing infected ticks, or through 
contact with infected human or animal blood and other tissues (Hoogstraal, 1979; Burney et al., 
1980; Khan, etal., 1997; Shepherd et al., 1985; Swanepoel etal., 1983a; Swanepoel etal., 1985a). 
Adult males are most commonly infected because of the occupational risk factor o f those employed 
in the livestock industry.
1.7.2. Transmission to non-human vertebrates
The host preferences o f the tick vectors of the virus play an important role in determining which
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vertebrates become infected. Species o f the genus Hyalomma, considered to be the main vectors of 
the virus, feed exclusively on small mammals and ground frequenting birds as immature ticks, while 
as adult ticks they feed on large mammals such as cattle, sheep, and goats, in preference to man and 
small mammals (Swanepoel et al., 1985b). Antibodies to CCHF virus are widely distributed in cattle 
sera in South Africa, and the only place that appears to have a consistently low prevalence of 
antibodies is along the southern coast, where Hyalomma marginatum rufipes is absent. However, 
given the mobility of man and his livestock today, clinicians can expect to encounter CCHF infection 
virtually anywhere in South Africa (Swanepoel et al., 1985a). To date a total of 158 cases o f CCHF 
have been confirmed in southern Africa from areas distributed throughout the region(unpublished 
laboratory records). The occurrence o f infections can be expected to occur in other geographic 
regions where the vector of this virus is distributed however data from serological surveys is not 
available as the ability to perform these tests is restricted to a limited number o f laboratories partly 
because of the lack o f safe reagents (Swanepoel, 1998). Recent outbreaks have been documented in 
the United Arab Emirates in 1994-1995 (Rodriguez etal., 1997; Khan etal., 1997) and more recently 
an outbreak occurred in Kosovo 2000 (unpublished).
Serological evidence of CCHF infection has been detected in many wild vertebrates, and the 
occurrence of viraemia has been demonstrated experimentally in several species (Hoogstraal, 1979; 
Saluzzo et al., 1985; Shepherd et al., 1989b).
1.7.3. Transmission by ticks to birds and the role of birds in dissemination of the virus
Birds play a role in the epidemiology of CCHF through serving as hosts for immature Hyalommas, 
and may help to disseminate infected ticks both locally and on long migration routes (Hoogstraal, 
1979; Zeller et al., 1994). Most birds do not develop demonstrable viraemia (Hoogstraal, 1979; 
Zeller et al, 1994; Shepherd et al., 1987a), but following the occurrence of an outbreak o f CCHF 
among workers at an ostrich slaughterhouse it was found that experimentally infected ostriches 
developed viraemia that was detectable on days 1-4 following subcutaeous inoculation o f virus 
(Swanepoel et al., 1998). As a consequence of this incident the European Union requires that 
imported ostrich meat must be derived from birds that have been treated and kept tick-free for 14
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days prior to slaughter, and that imported live ostriches must be free o f antibody to CCHF virus 
(Swanepoel et al., 1998; Capua, 1998).
1.7.4. Transmission of virus from animals to ticks
Although livestock and small mammals develop viraemic infection, humans and suckling mice are 
the only species for which CCHF virus is pathogenic (Watts et al., 1989). Many species of ticks have 
been shown to be capable of transmitting CCHF experimentally (Hoogstraal, 1979). In a study done 
by Shepherd et al. (1991) it was shown that infected cattle and scrub hares could serve as a source 
of virus for infection o f five South African species of ticks through the ingestion o f viraemic blood 
meals {H. truncatum, H. m. rufipes, Amblyomma hebraeum, Boophilus decoloratus, Rhipicephalus 
evertsi evertsi and R. appendiculatus), but subsequent transmission of infection to a susceptible host 
was demonstrated for only one species, H. m. rufipes. Shepherd et al. (1991) failed to demonstrate 
transovarial passage of virus from one generation of ticks to the next, a mechanism which can ensure 
perpetuation o f the virus even in the absence of viraemic hosts. However, regardless o f whether they 
transmit virus transovarially, infected ticks survive for long periods away from hosts, and can thus 
ensure perpetuation o f virus in the environment from one season of tick activity to the next.
1.8. Pathogenesis
The pathogenesis of the disease is incompletely understood (Joubert, et al., 1985; Swanepoel et al., 
1989), but by analogy with other arthropod-borne virus infections it can be surmised that peripherally 
introduced CCHF virus must undergo some replication at the site o f inoculation, and that 
heterogenous and lymph-borne spread of infection occurs to major sites o f replication. It has been 
found that the major targets o f infection are macrophages, hepatocytes and endothelial cells (Burt 
et al., 1997), with consequent platelet activation and triggering o f the intrinsic coagulation cascade 
leading to the development of disseminated intravascular coagulopathy (DIC). Formation of 
circulating immune complexes with complement activation probably accounts for the occurrence of 
a rash and further contributes to the damage of capillary bed and the genesis o f renal and pulmonary 
failure (Swanepoel, 1994; Joubert et al., 1985). Widespread tissue damage in organs such as the liver 
results in the release o f procoagulants into the bloodstream and further impairment o f the circulation
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through promoting DIC. Liver failure results in limited clearance of fibrin degradation products and 
impaired synthesis o f coagulation factors to replace those which are consumed (Swanepoel, 1984).
1.9. Disease in humans
1.9.1. Clinical features
The incubation period between tick-bite and onset of illness is generally very short, 2-3 days, and 5-6 
days (maximum 13 days) following contact with infected tissues of livestock or human patients.
The onset of illness is extremely sudden, with a severe headache usually being the earliest symptom, 
frequently accompanied by dizziness, neck pain and stiffness, sore eyes and photophobia (Swanepoel 
et al., 1987; 1989). Fever is constant, diphasic or irregular, with rigors and chills evident at the same 
time or shortly thereafter. Patients rapidly develop general myalgia and malaise, with intense 
backache and leg pain. Nausea, sore throat and vomiting not associated with eating, liquid stools and 
loss of appetite are common at the onset of illness and about half of the patients experience non- 
localised abdominal pain. Patients experience sharp change of mood, with feeling o f confusion and 
aggression, some even have bouts of violent behaviour (Swanepoel et al., 1987; 1989). After 2-4 
days of illness patients often exhibited lassitude, depression and somnolence. Hyperaemia of the face, 
neck and chest, congested sclerae, conjuctivitis, a slightly hyperaemic pharynx and spotted 
enanthemas on the soft and hard palate are common. A macular rash appears on the trunk about 5 
days after onset of illness. Tachycardia is common and there is a tendency for patients to be slightly 
hypotensive. Lymphadenopathy is recorded in some patients, with moderate swelling of inguinal, 
axillary and or cervical glands. Right upper quadrant tenderness o f the abdomen and hepatomegaly 
is discernible in about half o f patients. Haemorrhage can present as petechia to large haematomas 
on the mucous membranes and the skin, and at injection and pressure sites. Intestinal haemorrhage 
(melaena) and uterine haemorrhage can occur, and sometimes haematemesis. The more severely ill 
patients enter a state of hepatorenal failure from about day five onwards and progressively become 
drowsy, stuporous and comatose. Jaundice is noted in the second week in some patients (Swanepoel 
etal., 1987; 1989; 1998).
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Reported death rates range from 25-50%, and deaths occur from day 5-14 of illness. Factors 
contributing to the fatal outcome include cerebral haemorrhage, severe anaemia, severe dehydration 
and shock associated with protracted diarrhoea, lung oedema and pleural effusion. Patients who die 
are reported to have developed multiple organ failure including cerebral, liver and kidney failure, and 
cardiac and pulmonary insufficiency (Swanepoel et al., 1987). In patients that recover convalescence 
usually progresses rapidly from about day 10-15 after onset of illness.
1.9.2. Clinical pathology
Leucocyte counts fall progressively during the period from day 3-12 o f illness, with absolute 
lymphopenia tending to precede neutropenia. Thrombocytopaenia is a consistent feature o f the 
infection and counts fall below 100X109 platelets/1 in most patients at some stage during the period 
from day 3 to 15 of illness. Most patients show a decline in haemoglobin level during the second 
week of illness, even in instances where overt haemorrhage is not a marked feature of the disease. 
Fibrinogen levels decline and become very low in fatal cases. The most noteworthy findings in the 
study by Joubert et al. (1985) relate to the grossly abnormal prothrombin ratio (PR), activated partial 
thromboplastin time (APTT), thrombin time (TT), fibrinogen, and fibrinogen degradation products 
(FDP) recorded from an early stage o f illness in fatal infection.
Patients have elevated serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and 
gamma-glutamyl transferase (yGT) values early in the disease. AST and ALT values >1000 U/l are 
associated with fatal outcome. Hyperbilirubinaemia and in some instances jaundice, became evident 
from day 9 onwards and there is an increase in both total and direct bilirubin readings. Serum 
creatinine kinase (CK) levels are markedly elevated in the second week o f illness (Swanepoel, et al., 
1987; 1989). Total serum protein and albumin levels are moderately depressed during the first week 
of illness, but are elevated from the end of the second week onwards. Irregular increase in blood urea 
level is observed from day three onwards, and there is a clear tendency for the level to be elevated 
from the end o f the second week (Swanepoel et al., 1987).
1.9.3. Viraemia and antibody response
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Viraemia has been detected in patients from the time of onset up to day 13 of illness, with highest 
titres occurring during the first 5 days, and a maximum recorded intensity o f 106 2mouse intracerebral 
LD50 (Swanepoel, 1998). Antibody, both IgG and IgM, become demonstrable by indirect 
immunofluorescence (IF) from about day 7 o f illness, and are present in the sera of all survivors of 
the disease by day 9 at the latest, while antibody response is generally not demonstrable in fatal cases 
(Burt, etal., 1993; Shepherd etal., 1989c). Antibodies are occasionally demonstrable slightly earlier 
than day 7, particularly by enzyme-linked immunosorbent assay (ELISA). The IgM antibody activity 
declines to undetectable levels by the fourth month after infection, and IgG titre may begin to decline 
gradually at this stage, but remains demonstrable for at least 5 years. Recent or current infection is 
confirmed by demonstrating seroconversion or a four fold or greater increase in antibody titre in 
paired serum samples, or IgM antibody activity in a single sample. Although patients with fatal 
infections often fail to mount a detectable antibody response it should be noted that they sometimes 
succumb before the seventh day of illness when antibody is first demonstrable in survivors. Among 
fatal cases in which antibody was detected, some patients had received multiple transfusions of 
immune plasma and developed moderate levels of IgG antibody, but exhibited nil or weak and 
transient IgM antibody activity so that it appears unlikely that endogenous antibody response had 
occurred (Swanepoel et al., 1987).
1.10. Disease in non-human mammals
Although humans can acquire infection with CCHF virus after contact with infected tissues of 
livestock and wild animals there is no evidence that the virus produces disease in these animals. 
Antibody surveys among livestock in endemic areas have shown high prevalences among both cattle 
and sheep (Swanepoel et al., 1987). Experimental studies have confirmed that sheep and cattle 
develop mild infection (Shepherd et al., 1987b), but they are briefly viraemic and hence can act as 
a source of infection for man. The danger is increased if  animals are slaughtered or die from other 
causes during CCHF infections and are then butchered. The virus does not survive well in tissues 
after death and there has been no indication that CCHF constitutes a hazard in meat processed and 
sold according to normal health regulations (Swanepoel et al., 1987).
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Experimental viraemic CCHF infection has been demonstrated in small wild vertebrates that are 
hosts for the immature stages of the tick vectors, and viral and serological surveys suggest that hares 
and hedgehogs become infected (Shepherd et al., 1987b).
1.11. Diagnosis
Rapid diagnosis of CCHF infection is important so that appropriate therapy can be instituted quickly, 
and the patient can be placed in isolation and treated under conditions o f barrier-nursing for the 
protection o f health workers and the community at large. Etiologic investigation o f the disease is 
undertaken in maximum security (biosafety level 4, or BSL4) laboratories in countries which have 
appropriate biosafety regulations and facilities.
Until comparatively recently laboratory diagnosis of the infection in live patients consisted solely of 
the isolation o f the virus from serum or plasma samples taken early in the disease, or demonstration 
of antibody seroconversion or a four-fold increase in antibody titre in paired samples, or 
demonstration o f IgM antibody activity. However, certain problems are encountered in attempts to 
achieve a specific diagnosis rapidly by conventional techniques. Most patients that succumb to 
infection fail to develop an antibody response, and isolation of virus by inoculation of infant mice 
is generally slow, with incubation periods of 7-9 days (Shepherd et al., 1986). Isolation of virus can 
be achieved more rapidly by inoculation of cell cultures (1-6 days) if  viraemia is intense, but more 
often virus is present in low concentration and can only be isolated by inoculation o f mice which are 
more sensitive than cell cultures (Shepherd, et al., 1986; Swanepoel et al., 1987).
Problems encountered in the isolation of virus can be overcome by the use o f sensitive techniques, 
such as ELISA, or reversed passive haemagglutination, to detect viral antigens in clinical specimens 
from CCHF patients (Shepherd et al., 1988). However, more recently rapid diagnosis in the acute 
stage of the disease has been achieved by detection o f viral RNA amplified by reverse transcriptase 
polymerase chain reaction (RT-PCR) (Schwartz, et al., 1995; Burt et al., 1998).
Among the methods used historically for demonstrating antibody to arthropod-borne viruses CF and
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immunodiffusion tests lack sensitivity and are unsuitable for detecting early antibody response, while 
production of haemagglutinin for HAI tests has proved to be difficult for CCHF virus and the tests 
lack reproducibility (Casals and Tignor, 1974; Swanepoel et al., 1983b). Reversed passive 
haemagglutination inhibition has been used for demonstrating antibody to CCHF virus, but the test 
also lacks reproducibility and amenability to automation, and has not found wide application 
(Gaidamovich et al., 1974; Swanepoel et al., 1983b). Nairoviruses in general, including CCHF, do 
not induce strong neutralizing antibody responses, and the sera o f many species contain non-specific 
inhibitors of virus infectivity which complicate neutralization tests (Swanepoel et al., 1983b; 
Swanepoel, 1998). Moreover, neutralization tests take too long to yield useful results when a rapid 
diagnosis is required. The IF test can be used to distinguish between IgG and IgM antibodies, and 
is useful for making rapid diagnoses in individual or small numbers o f suspected cases o f the disease 
(Swanepoel et al., 1987; Shepherd et al, 1988; Burt et al., 1994), but the reading of the test is 
subjective, and the technique is not well suited to conducting large serosurveys. These problems were 
potentially overcome by the development o f a solid-phase radioimmunoassay and indirect or 
sandwich ELISA, and the ELISA has found practical application for the demonstration of antibodies 
in human sera for diagnostic and survey purposes (Donets et al., 1982; Shepherd et al., 1988; Burt 
et al., 1994). Moreover, the use o f commercially available anti-species immunoglobulin peroxidase 
conjugates makes it possible to apply the ELISA to serosurveys on livestock sera, while a 
competitive or blocking ELISA (CELISA) can be used to test sera of species such as ostriches for 
which no conjugates are available (Burt et al., 1993; Swanepoel et al., 1998).
1.12. Differential diagnosis
The disease should be distinguished from tick-borne typhus (rickettsial infection) which has an 
incubation period o f 7-10 days and more insidious onset than CCHF. Rift Valley fever can also be 
acquired from contact with the tissue o f livestock in Africa, but this usually occurs in the context of 
a massive epizootic involving abortion and death of sheep and cattle at irregular intervals of years 
when heavy rains favour the breeding of the mosquito vector of the virus (Swanepoel, 1994). Many 
other infectious conditions of humans may present as haemorrhagic disease resembling CCHF, 
including bacterial septicemias, but o f special interest are the so-called viral haemorrhagic fever
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(VHF) of Africa and Eurasia. They include Marburg and Ebola fever caused by members o f the 
family Filoviridae, Lassa fever caused by a virus of the family Arenaviridae, haemorrhagic fever 
with renal syndrome (HFRS) caused by members o f the Hantavirus genus of the family 
Bunyaviridae. Distinguishing between the various possible causes of suspected cases of VHF is 
specialised task, normally undertaken in laboratories which are equipped for the purpose (Swanepoel, 
1994).
1.13. Recombinant baculovirus expressed antigen
Recombinant polypeptides are being used with increasing frequency as diagnostic antigens and have 
the advantage that they are non-hazardous, and indeed there have already been attempts to use 
recombinant antigens for detecting antibodies to CCHF and a related nairovirus, Dugbe, but the 
CCHF reagents lacked sensitivity and have not found application (Marriott, et al., 1992; Ward et al., 
1992). Baculoviruses (of the family Baculoviridae) are insect-specific viruses which have become 
o f great interest due to their usefulness as biopesticides and recombinant protein expression vectors. 
They are widely used as eukaryotic vectors for the expression of a variety o f foreign genes. In most 
cases such vectors have resulted in high levels o f protein being produced which, with few exceptions, 
are correctly processed and biologically active. The expression system is based on replacing the 
highly expressed viral polyhedrin gene with a recombinant gene consisting o f the polyhedrin 
promoter fused upstream to the desired foreign coding sequence. Since the polyhedrin gene is 
dispensable for viral replication, the ensuing recombinant virus is fully infectious and at late times 
of infection the activated polyhedrin promoter directs efficient transcription of the foreign gene (Patel 
et al., 1991). Expression of the foreign gene is usually driven by the polyhedrin promoter o f the 
autographa californica nuclear polyhedrin virus (AcNPV), which is highly transcribed during the late 
stages o f infection. AcNPV has a large circular double stranded DNA genome with multiple 
recognition sites for many restriction endonucleases, and as a result, recombinant baculoviruses are 
traditionally constructed in a two stage process. First, a foreign gene is cloned into a plasmid transfer 
vector down-stream from a baculovirus promoter and flanked by baculovirus DNA derived from a 
non-essential locus, usually the polyhedrin gene. Second, this plasmid DNA is introduced into insect 
cells along with wild-type genomic viral DNA. Typically, 0.1-1% of the resulting progeny are
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recombinants with homologous recombination in vivo. Recombinant viruses containing the foreign 
gene inserted into the polyhedrin locus can be identified by an altered plaque morphology, which is 
characterised by the absence o f occluded virus in the nucleus of the infected cells, and the 
recombinant virus is purified to homogeneity by sequential plaque assay (Luckow et al., 1993).
Recombinant antigens are being used more frequently as diagnostic antigens, and it was decided to 
evaluate the use o f a recombinant antigen as a diagnostic tool for CCHF virus infection in human 
patients, and for serological surveys o f domestic livestock and wild animal sera for antibody to the 
virus. It had previously been shown using monoclonal antibody studies that the nucleocapsid is the 
most highly conserved viral protein (Blackburn et al., 1987), and is therefore the most useful for 
diagnostic assays. Hence it was decided to investigate baculovirus systems expressing the CCHF 
nucleocapsid protein as the antigen o f choice.
1.14 Objectives
Due to the biohazardous nature of VHF viruses all diagnostic reagents must be prepared within the 
confines of BSL4 laboratories, and inactivated and safety tested before they can be used in other 
laboratories. There are a limited number of BSL4 laboratories worldwide and for this reason reagents 
that are safe to produce and use would be of great value, not only as diagnostic tools, but also for use 
in serosurveys and for the testing of livestock and wild animal sera as a prerequisite to the export of 
live animals. In recent years the SPU has diagnosed cases o f the disease or found serological evidence 
of the presence of the virus in several countries in Africa and in the Middle East, including Iraq, Iran, 
Afghanistan, and Pakistan (unpublished laboratory records). Few, if any, of these countries can afford 
to establish BSL4 laboratories of their own, and the SPU has received several requests from health 
authorities in these countries, and the World Health Organization in Geneva, to be o f assistance in 
developing safe diagnostic procedures which can be used in laboratories which are less sophisticated 
than BSL4 laboratories, but which could nevertheless provide adequate protection for laboratory 
personnel. Hence, it was decided to explore the use o f recombinant antigen for the diagnosis of 
CCHF virus infection in human patients, and for the screening of livestock and wild animal sera for 
antibody to the virus. For purposes o f determining the sensitivity and specificity o f tests for antibody 
to CCHF virus using recombinant antigen, the tests using sucrose acetone antigen were regarded as
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the gold standard. A previous publication investigating several methods for demonstrating antibody 
to CCHF virus in serum samples from confirmed patients showed that the ELISA was a sensitive test 
for detecting an antibody response (Burt et al., 1994). It is extremely difficult to provide the perfect 
cohort of specimens with an infection such as CCHF in humans. The number o f infections annually 
is very small, and the specimens submitted from patients is limited, hence the evaluation is based on 
availability of specimens. Statistically significant numbers are unrealistic in a laboratory dependent 
on natural infections of CCHF in humans and experimental infection of sheep and mammals with 
a highly infectious agent such as CCHF. For experimental infections the animals must be confined 
for the duration of the experiment and hence logistics do not allow large numbers to be of these 
animals to be analysed.
The SPU is in a particularly favourable position to conduct research on assays for antibody to CCHF 
virus because it has a unique collection of serum samples derived from confirmed CCHF patients, 
as well as from experimentally infected livestock and small mammals. For this reason, BSL4 
laboratories abroad which had produced candidate recombinant CCHF antigens asked the SPU to 
evaluate the antigens: the Virology Division, United States Army Medical Research Institute for 
Infectious Diseases (USAMRIID), Fort Detrick, Maryland, USA, supplied a baculovirus recombinant 
expressing an insert from the S segment of the CCHF genome coding for the nucleocapsid protein, 
while the Special Pathogens Branch, Centres for Disease Control (CDC), Atlanta, Georgia, USA, 
supplied three recombinant nucleoprotein antigens. The initial purpose of the present study, therefore, 
was to evaluate the reagents received from abroad, but in case none of them proved to be satisfactory 
it was decided to attempt production o f further recombinant antigen at the same time. Consequently, 
the study comprised:
1. Expression of the nucleoprotein o f CCHF virus as a recombinant for use as a non-hazardous 
diagnostic reagent.
2. Development of IgG and IgM ELISA for the serodiagnosis of CCHF infection, using recombinant 
antigens.
3. Evaluation o f ELISA for detection o f IgG and IgM antibody to CCHF virus using stored serum 
samples from confirmed CCHF patients and experimentally infected small mammals and livestock.
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2.0 Materials and methods
2.1. Recombinant reagents
A baculovirus transfer plasmid, designated CCHF pBlueBac, containing a 1510 base pair (bp) 
segment of the CCHF S segment inserted at an Nhel restriction site was supplied as a glycerol stock 
of INV alphaF’ Escherichia coli by Dr J. Smith of the Virology Division, United States Army 
Medical Research Institute for Infectious Diseases (USAMRIID).
A recombinant baculovirus, designated BacCCHFl, expressing the nucleocapsid protein of CCHF 
virus was also supplied by Dr Smith of USAMRIID. The CCHF nucleocapsid protein expression and 
purification is described below in Section 2. Autographa californica nuclear polyhedrosis virus 
(AcNPV) was used as the control baculovirus.
Three CCHF virus recombinant antigens were supplied by Dr S. Nichol, Special Pathogens Branch, 
Centres for Disease Control (CDC), Atlanta, Georgia. The antigens had been characterised but had 
not been evaluated because of lack o f suitable reagents, hence they were donated as a gift for 
evaluation in ELISA for detection of specific antibody using clinical sera from confirmed CCHF 
patients. The three recombinant antigens supplied were as follows:
1. a full length CCHF nucleocapsid protein that was expressed in E. coli M l5 (Qiagen, Hilden, 
Germany),
2. a full length CCHF nucleocapsid protein that was expressed in E. coli SG 13009 (Qiagen),
3. a 63 amino acid fragment of nucleocapsid protein coded by nucleotides 689-879 of the S segment 
of the genome of CCHF strain 10200, that was expressed in E.coli. The nucleotide was expressed 
behind dihydrofolate reductase carrier protein to protect the peptide from degradation in E. coli.
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2.2. Antisera and antigens
Monoclonal antibody, 5G2, specific for viral nucleocapsid protein was used as a coating antibody 
in the ELISA (Blackburn et al., 1987). The antibody was stored freeze dried at -70°C. Anti-CCHF 
hyperimmune mouse ascitic fluid (HMAF) previously prepared for unrelated studies was stored 
freeze dried at -70° C and used as a detection antibody in the IgM-capture ELISA.
Guinea pig immune sera from animals hyperimmunised against Dugbe, Hazara and Nairobi sheep 
disease viruses were previously prepared for unrelated studies and stored freeze dried at -70 °C. These 
immune sera were used to determine the antigenic specificity o f the recombinant antigen.
Sucrose acetone extracted antigen was previously prepared for unrelated studies from suckling mouse 
brain infected with a South African human CCHF isolate 4/81 (Swanepoel et al., 1983a), inactivated 
with 0.1% beta-propriolactone (Clarke et al. ,1958) and stored freeze dried at -70 °C. Control antigen 
was prepared from non-infected mouse brain.
Anti-CCHF horseradish peroxidase (HRPO) conjugate was prepared by the method o f Wilson and 
Nakane (1978) from serum which had been collected from rabbits hyperimmunised with CCHF virus 
for an unrelated project, and stored at -70°C. The immunoglobulin fraction was isolated from pooled 
immune rabbit serum by ammonium sulphate precipitation (31%, pH 7.4) o f the IgG fraction. The 
serum was diluted 1:2 with distilled water, 31 % ammonium sulphate was added and the solution left 
to stand for 30 minutes at room temperature. The solution was centrifuged for 30 minutes at 5000x g 
in a high speed Beckman centrifuge, model J2-21, rotor JA 21 (Beckman, California, USA), the 
supernatant discarded and the precipitate dialysed against carbonate buffer, pH 9.6, for seven days 
at 4°C. Four micrograms of HRPO Sigma type IV (Sigma Chemical Company, St. Louis, USA) was 
dissolved in 1 ml o f distilled water. A 200[A aliquot of freshly prepared 0.1 M sodium periodate 
(Sigma) was added and incubated at room temperature for 30 minutes. The HRPO-aldehyde solution 
was dialysed against 1 mM sodium acetate, pH 4.4, overnight at 4°C. Sufficient carbonate buffer was 
added to increase the pH of the solution to 9.5. The pH was determined using Merck Neutralit pH 
paper, range o f pH 5-10 (Merck, Frankfurter, Darmstedt, Germany). A 1 ml aliquot o f purified rabbit
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immunoglobulin (previously dialysed against carbonate buffer) was immediately added and left at 
room temperature for 2 hours. The solution was dialysed against phosphate buffered saline (PBS) pH 
7.4 (Appendix A), for 7 days and the anti-CCHF HRPO conjugate was stored at -70°C.
2.3. Serum samples
A total of 295 human sera tested in the study included: 135 human serum samples from cases of 
CCHF diagnosed between 1981 and 1999 in SPU, collected at various intervals from the day of 
illness as shown in Figure 1, and 160 sera from non-CCHF patients submitted to the Special 
Pathogens Unit that had previously been tested routinely on submission to the laboratory for antibody 
activity to CCHF and virus isolation attempts were performed by inoculation of suckling mice and 
cell culture. No evidence o f CCHF infection was obtained in any of the sera from non-CCHF 
patients. All serum samples were stored at -70° C. The sera were tested by ELISA for IgG and IgM 
antibody and by competitve ELISA (CELISA) for total antibody activity to CCHF virus using both 
a sucrose acetone extracted antigen and a recombinant antigen as described below.
A total of 271 ostrich serum samples were included in the study. The ostrich sera were submitted to 
SPU from 1981 to 1999 to test for antibody to CCHF virus as one of the requirements for permission 
to export the ostriches. The sera were stored at -70°C. Ostrich serum samples were tested for 
antibody activity to CCHF virus by CELISA using each antigen to evaluate the recombinant 
CCHFantigen in the ELISA.
A total of 63 sera from 3 experimentally infected sheep were tested by ELISA for IgG and IgM 
antibody to CCHF virus. The sheep had been experimentally infected for an unrelated study and 
sampled daily from day 0, the day o f inoculation with CCHF virus until day twenty-eight, and 
monthly from month four to month eight. Samples were collected on day 0, prior to inoculation, in 
order to be used as controls and provide baseline results for each individual sheep. The sera were 
stored at -70°C.
Total antibody screening was performed on 35 sera from experimentally infected small mammals.
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The serum samples were collected from the following mammals: Mystromys albicaudatus (White­
tailed rat), Tatera brantsii (Bushveld gerbil), Tatera leucogaster (Highveld gerbil) and Aethomys 
namaqueisis (Namaqua rock mouse) on days after inoculation as indicated in the results section. The 
mammals were experimentally infected with CCHF virus for an unrelated study and the serum 
samples were stored at -70°C.
All serum samples listed in Section 2.3 were collected for unrelated studies and were stored wet at - 
70°C.
2.4. Preparation of CCHF baculovirus recombinant
An attempt to prepare a recombinant baculovirus system for expression o f the CCHF nucleocapsid 
protein was performed using the Bac-To-Bac Baculovirus Expression System (Bac-To-Bac™ 
Baculovirus Expression System, GibcoBRL, Paisley, UK) according the manufacturer’s protocol. 
The 1510 bp region of the CCHF S segment coding for the nucleocapsid protein excised from the 
pBluebac baculovirus transfer plasmid by digestion with Nhe I (GibcoBRL) restriction enzyme was 
cloned into a pFastBac 1 (GibcoBRL) donor plasmid. A restriction map illustrating the pBluebac 
plasmid is provided in Appendix A.
2.4.1. Isolation of S segment of CCHF virus genome from pBluebac plasmid
The CCHF pBlueBac plasmid was initially grown in broth to obtain a large volume from which the 
DNA was purified to remove broth constituents such as salts and concentrated to a volume suitable 
for digestion with the restriction enzyme to obtain the CCHF insert. The plasmid was grown by 
inoculation o f 5 ml Luria-Bertani (LB) broth (Appendix A) containing 100 /ig/ml ampicillin, 
incubated overnight at 37 °C and the following day a 0.5 ml aliquot was inoculated into 150 ml of 
LB broth containing 100 jig/ml ampicillin and incubated overnight at 37 °C. The cells were harvested 
by centrifugation of the suspension at in a high speed centrifuge 3000x g (Beckman) for 30 min and 
lysed in 8 ml of lysosome solution (Appendix A) on ice for 30 minutes. Two volumes of 0.2M
18
20
1 3 5 7 9 11 13 15 17 19 21 1 3 5 7 9 1
Days Months Year
Figure 1. Histogram showing the number of serum samples included in the study which has 
been collected from CCHF virus infected patients from 1986 to 1999 at the indicated 
interval after the onset o f illness.
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sodium hydroxide containing 1% SDS were added to the lysed cells and kept on ice for 5 minutes. 
A 12 ml aliquot of 3M sodium acetate, pH 4.8, was added and the mixture held for a further 30 
minutes on ice. Aliquots of the cell suspension were centrifuged for 10 minutes at lOOOOx g 
(Beckman) and nucleic acid was precipitated from supernatant fluid using 2.5 volumes o f 96% 
ethanol and incubated at -70 °C for 1 hour. The precipitate was resuspended in 12 ml of Tris-EDTA 
(TE) buffer, pH 8.0 (Appendix A) and clarified as previously described. The DNA was precipitated 
by adding 5 ml of 7.5 M ammonium acetate and holding for 30 minutes on ice. The solution was 
centrifuged as above at 1 OOOOx g for 10 minutes and the DNA precipitated from the supernatant fluid 
with 2.5 volumes of ethanol at -70°C for 1 hour. The precipitate was washed with 80% ethanol, 
followed with a wash in absolute alcohol, dried and resuspended in 1 ml of TE buffer. The DNA was 
quantitated spectrophotometrically assuming that an optical density reading o f 1 at a wavelength of 
260 nm correspond to approximately 50/ig/ml for double stranded DNA. The DNA concentration 
was then adjusted to contain l/ug DNA in a volume of 20 /A (Maniatis, 1982). A 20 fA aliquot of 
purified plasmid which contained the CCHF insert was digested with Nhe 1(10 units//il) enzyme 
(GibcoBRL). The following volumes were added into the microcentrifuge tube for digestion : 20/il 
of purified plasmid, 3/A of 10X enzyme buffer, 2 fA of Nhe I enzyme and 5/A o f water. The reaction 
was incubated for 1 hour at 37 °C waterbath. A 70/A aliquot of water was added to make up the 
volume to 100//1. A further 100//1 each of TRIS saturated phenol and chloroform were added and 
centrifuged at lOOOOx g for 10 minutes. The aqueous layer was precipitated with 1.5 volumes of 
isopropanol and incubated at -20°C for 1 hour. Centrifugation was carried out at lOOOOx g in an 
Eppendorf Microcentirfuge (Sigma-Aldrich, EschestraBe, Germany) for 15 minutes, the pellet dried 
and resuspended in 10/H of water. The DNA was then separated by electrophoresis using a 0.8% 
agarose gel (FMC Bioproducts, Rocklands, ME, USA) prepared in TAE buffer (Appendix A) 
containing 0.5 /ig/ml ethidium bromide. The CCHF segment (1510 bp) was excised from the gel into 
a microcentrifuge tube and 400//1 of TAE buffer added. The tube was heated for 5 minutes at 65 °C. 
A 400^1 aliquot o f TRIS saturated phenol was added and centrifuged as before in a microfuge 
(Sigma). A further 400/H aliquot of chloroform and 400/A aliquot of phenol was added to the 
aqueous layer and centrifuged as above. The aqueous layer was precipitated in 2.5 volumes of ethanol 
and incubated at -20 °C for 1 hour. The pellet was dried and resuspended in 10/^ 1 o f water.
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2.4.2. Cloning of CCHF virus insert into pFASTBAC 1 donor plasmid
The pFASTBAC 1 expression vector (GibcoBRL) was digested with Xba I enzyme (12 
units//ul)(GibcoBRL). The following volumes were added into the microcentrifuge tube for digestion: 
2 A  of purified vector DNA, \A  o f 10X enzyme buffer, l A  of Xba I enzyme and 6 A  of water. The 
reaction mixture was incubated for 1 hour in 37° C. A 90/H aliquot of water was added to make up 
the volume to 100/H. A further 100/il of TRIS saturated phenol and chloroform was added to the tube 
and centrifuged at lOOOOx g in a microfuge (Sigma) for 10 minutes. The aqueous layer was 
precipitated with 1.5 volume o f isopropanol and incubated at -20° C for 1 hour. Centrifugation was 
then carried out as above, the pellet was dried and resuspended in 10/ft of 10 mM TRIS-HC1, pH 8.0. 
To dephosphorylate the vector, a 5 /A aliquot o f the digested and purified DNA vector was added to 
5 A  of 10X calf intestinal alkaline phosphatase (CIP) buffer (Appendix A), 48 A  of water and 2 A  
of CIP. After 30 minutes o f incubation at 37°C, a further 2 A  of CIP was added and the tube 
incubated for 30 minutes at 37 °C. A 40 A  aliquot of water, 10 A  o f STE buffer (Appendix A) and 
5 A  ° f  10% SDS were added to the tube. The tube was then heated to 68° C for 15 minutes. The 
DNA was then extracted twice with phenol/chloroform and twice with chloroform. The DNA was 
precipitated with ethanol and ready for ligation. To ligate the insert and the vector, a 5A  aliquot of 
DNA (insert recovered from the gel) and 2>A aliquot of pFASTBAC 1 vector (that was 
dephosphorylated) were added in a microcentrifuge tube and warmed for 5 minutes at 45° C to melt 
the cohesive termini that has reannealed. The tube was then chilled on ice. A l,ul aliquot of T4 DNA 
Ligase (Roche Diagnostics, Manheim, Germany) and 1A  of 10X ligase buffer was added to the 
microcentrifuge tube. The reaction mixture was incubated for 16 hours at 4°C. The DNA was then 
ready to be used for transformation.
2.4.3. Transformation of DH5« competent cells
The DH5<* competent cells (GibcoBRL) and pUC19 DNA (GibcoBRL) were stored at -70°C. The 
competent cells was removed from -70° C and thawed on wet ice. The cells were gently mixed, then 
100 A  ° f  competent cells were aliquoted into the chilled microcentrifuge tubes. A 5 A  aliquot of 
control pUC 19 (GibcoBRL) was added to one tube containing 100 A  of competent cells to determine 
the transformation efficiency. The pipette was moved through the cells while dispensing and the tube
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tapped to mix. A 3 /u\ aliquot of the DNA ligation reaction was added to the second tube containing 
100 m1 of competent cells, moving the pipette through while dispensing and the tube tapped to mix. 
The mixture was incubated on ice for 30 minutes. Cells were heat shocked at 42°C for 45 seconds. 
The cells were then placed on ice for 2 minutes. A 0.95 ml aliquot of S.O.C. medium (Appendix A) 
was added and incubated for 1 hour at 37°C with shaking for expression. After expression, 0.1 ml 
of the reaction containing the control pUC19 was diluted with 0.9 ml medium. A 100/ft aliquots of 
the undiluted reaction and the 1/10 dilution were spread on Luria Bertani (LB) plates (Appendix A) 
with 100 //g/ml ampicillin and 50 /ug/ml 5-brom-4-chlor-3-indolyl-P-D-galactopyranosid (X-gal). 
The experimental reaction was diluted as was done with the control pUC19 cells (outlined above) 
and lOOAil o f cells spread on the agar plates as the control. The plates were incubated for 48 hours 
at 37°C. To confirm that the white colonies were truly white, they were selected and streaked on a 
plate and incubated as before. The confirmed white colonies (transformed DH5« cells) were picked 
and grown by inoculation of 5 ml LB broth containing 100 ng/vnX o f ampicillin and DNA was 
isolated as outlined in section 2.4.1. above. To confirm the presence of transformed DNA in the 
preparation, the isolated DNA was analysed by electrophoresis using a 0,8% agarose gel as described 
in Section 2.4.1. and a DNA band of approximately 20 000 base pairs confirms the presence o f the 
transformed DNA in the preparation.
Amplification by polymerase chain reaction (PCR) using primers specific for a region o f the CCHF 
S segment was performed to confirm the presence o f the CCHF insert. The primer pair designated 
F2(5' ACACCTTCACAAACTC 3') and R3 (5' GACAAATTCCCGCACCA 3') have previously been 
described and amplify a 536 base pair region of the nucleocapsid gene (Burt et al., 1995). Briefly a 
3 /^ 1 aliquot o f template was amplified in a tube containing the following reaction mix: 5/A o f 10X 
PCR buffer, 1 Ail of 1 OmM dNTP mix (1 OmM each dATP, dTTP, dCTP, dGTP) (Roche Diagnostics), 
1.5iA 50 mM MgCl2, 2.5^1 o f primer mix (1.25/^1 each 10/ftVl stock) and 0.5/ft Taq Polymerase (2.5 
U)(Promega Corporation, Madison, WI, USA). Distilled water was added to final volume of 50/fi. 
The content of the tube was mixed by gentle tapping of the tube. After incubation at 95 °C for 3 
minutes, 30 cycles of PCR were performed as follows: 94 °C for 30 seconds, 47 °C for 30 seconds 
and 68°C for 3 minutes. A final extension o f 68°C for 7 minutes. The PCR product was visualised
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by electrophoresis using a 0.5% agarose gel (FMC Bioproducts) in TAE (Appendix A) buffer 
containing 0.5 /ig/ml ethidium bromide. A positive was control was prepared using CCHF RNA 
extracted from infected tissue culture (stored in the Special Pathogens Unit). The RNA was reverse 
transcribed to cDNA using the CCHF primer F2, M-MLV Reverse Transcriptase, Superscript (Gibco 
BRL) and the following conditions: 1 pmol F2 primer, 5 /il RNA template made up to 10/il with 
water and heated at 95 °C for 3 min, cool 42 °C for 3 min. To the tube the following were added, 1 
/A RNasin (Roche Diagnostics), 4 /il 5x buffer (Gibco BRL), 2 /A of 10mm dNTP mix (Roche 
Diagnostics), 2 /A 0.1 M dithiothreital (GibcoBRL) 1 /il M-MLV reverse transcriptase (GibcoBRL). 
The tube was mixed, incubated for 30 min at 42 °C, heated for 3 min 95 °C and the reaction 
quenched on ice for 3 min. The cDNA was amplified using PCR as described above, 1 /il of template 
was used in the PCR reaction.
2.4.4. Transformation of DHlOBac competent cells
The DHlOBac competent cells ( GibcoBRL) were stored at -70°C. The cells were removed from the 
freezer and thawed on wet ice. The cells were gently mixed, then 100 iA of competent cells added into 
the chilled polypropylene tubes. A 5/il aliquot of pUC 19 control DNA (GibcoBRL) was added to 100 
lA of competent cells to determine the transformation efficiency. To determine the transposition 
efficiency 5 /il of pFASTBAC-gus control DNA (GibcoBRL) was added to 100 /il of competent cells. 
The cells were incubated on ice for 30 minutes. Without shaking the cells were heat shocked at 42 °C 
for 45 seconds. The cells were then placed on ice for 2 minutes. A 0.9 ml aliquot of S.O.C. medium 
(Appendix A) was then added. Tubes from the ligation reaction and control were incubated at 37 °C 
with shaking for 4 hours. The reaction containing the pFASTBAC-gus control DNA was diluted at 
1/10, 1/100 and 1/1000 with S.O.C. medium and 100/il o f each dilution were spread on agar plates 
that contain 50/ig/ml of kanamycin sulphate, 10/ig/ml of tetracycline, 7/ig/ml of gentamycin, 
100/ig/ml of X-gal and 40 /ig/ml of IPTG. The transformation with the pUC19 control DNA was 
diluted at 1/10, 1/100 and 1/1000 and plated on agar with 100/ig/ml ampicillin. The experimental 
reactions were diluted as above and 100/il spread on agar that contain 50/ig/ml o f kanamycin 
sulphate, 10/ig/ml of tetracycline, 7/ig/ml of gentamycin, 100/ig/ml of X-gal and 40/ig/ml of IPTG. 
The plates were incubated at 37° C for 48 hours.
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White colonies were selected from the plate for isolation of recombinant bacmid DNA. Before 
isolating bacmid DNA, candidate colonies were re-streaked on a new plate to ensure that they are 
truly white. Using a sterile toothpick, a single isolated bacterial colony was inoculated into 2 ml LB 
medium supplemented with 50/ig/ml kanamycin, 7/ig/ml gentamycin and 10/ig/ml tetracycline. The 
cells were grown at 37°C for 24 hours with shaking. A 1.5 ml aliquot o f culture was transferred to 
a tube and centrifuged at 14000x g for 1 minute. The supernatant was removed by aspiration and 
resuspended by gently pipetting up and down in 0.3 ml of Solution I (Appendix A). A 0.3 ml aliquot 
of Solution II (Appendix A) was added and gently mixed. The tube was incubated at room 
temperature for 5 minutes. A 0.3 ml aliquot of 3 M potassium acetate, pH 5.5, was slowly added with 
gentle mixing during addition. The sample was placed on ice for 10 minutes and centrifuged at 
14000x g for 10 minutes. The supernatant was transferred into another microcentrifuge tube 
containing 0.8 ml of isopropanol. The tube was mixed gently ,placed on ice for 10 minutes, 
centrifuged at 14000x g in the Beckman high speed centrifuge for 15 minutes and the supernatant 
discarded. The pellet was washed with 0.5 ml of 70% ethanol. After washing and spinning, the 
supernatant was discarded and the pellet air dried and resuspended in 40/A o f TE. The DNA was 
stored at -20°C.
2.4.5. Analysis of bacmid DNA
To confirm the presence of bacmid DNA a 5/A aliquot of the Bacmid mini-prep (isolated in section
2.4.4.) was separated by electrophoresis using a 0.5% agarose (FMC Bioproducts) gel in TAE buffer 
containing 0.5/^g/ml ethidium bromide. The size of the bacmid DNA is approximately 23000 bp.
Verification of the insertion o f the CCHF gene was done by PCR using pUC/M13 amplification 
primers. To each tube, the following were added: 5/A o f 10X PCR buffer, 1 /u\ o f lOmM dNTP mix 
(lOmM each dATP, dTTP, dCTP, dGTP), 1.5 /A 50 mM MgCl2, 2 .5 (A of primer mix (1.25/ft each 
10/iM stock), 1/A template DNA and 0.5/ft Taq Polymerase (2.5 U)(Promega Corporation, Madison, 
WI, USA). Distilled water was added to final volume of 50/ft. The content of the tube was mixed by 
gentle tapping of the tube. After incubation at 95 °C for 3 minutes, 35 cycles o f PCR were performed 
as follows: 94°C for 45 seconds, 55°C for 45 seconds and 68°C for 3 minutes. PCR products were
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analysed by electrophoresis using a 0.7% agarose (FMC Bioproducts) gel in TAE buffer containing 
0.5yug/ml ethidium bromide. The predicted PCR products are as follows: the bacmid only is 
approximately 300 bp and the transformed bacmid is approximately 2300 bp. Each step of the 
protocol had been controlled as recommended by the manufacturers o f the Bac-to-Bac system, 
troubleshooting had been performed as suggested, however after numerous attempts the experiment 
was discontinued at this point as a positive PCR indicating that the bacmid was transformed was not 
demonstrable.
2.5. Expression and purification of recombinant antigen
2.5.1. Inoculation of cell cultures
The Sf9 cells [(Fall Armyworm Ovary, Spodoptera frugiperda) cells obtained from the American 
Type Culture Collection (ATCC) CRL 1711] were grown in T25 tissue culture flasks with 5 ml 
Grace’s medium (Sigma Chemical Company, St.Louis, USA) containing 10% foetal calf serum 
(FCS), fungizone 20 mg/ml and gentamycin 10 mg/ml, until the cells were confluent. Tissue culture 
flasks were inoculated with either 1 ml of recombinant baculovirus BacCCHFl expressing the N- 
protein o f CCHF virus, or with 1 ml o f AcNPV as a control. The inoculum was absorbed for 1 hour 
at 28° C. After 1 hour of incubation with regular shaking at room temperature, the inoculum was 
discarded and 5 ml o f Grace’s medium without FCS was added to the flasks and incubated at 28 °C 
for 6 days.
2.5.2. Detection of in  vitro  expression of CCHF nucleoprotein
Two methods were employed to show that the CCHF nucleoprotein was expressed from the 
baculovirus in cell culture: immunoflourescence was performed on infected cells to show expression 
o f protein and a Western blot was performed to confirm that the protein expressed reacted with 
mouse anti-CCHF serum and that the size o f the protein expressed was that predicted for CCHF 
nucleoprotein.
2.5.2.1. Immunofluoresence tests
Sf9 cells were inoculated on day 1 with baculovirus BacCCHF-1 as described in section 2.5.1. On
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day 2 after inoculation and on each subsequent day, cells were scraped from the tissue culture flask 
using a pasture pipette and approximately 0.5 ml of medium containing the scraped cells were 
transferred into a centrifuge tube. Cells were scraped from flasks infected with the wild type AcNPV 
and used to prepare control slides for immunofluorescence. The tubes was centrifuged for 5 minutes 
at 3000x g. The medium was discarded and the cells resuspended in 100^1 of 2% foetal calf/saline. 
Ten microlitres of the cell suspension was applied to each well of 8-well multi-test slides (Flow 
Laboratories, Irvine, UK), dried for 20 minutes at 37°C and fixed in cold acetone for 20 minutes. For 
the IF test, 10/^ 1 of anti-CCHF HMAF diluted 1/10 in PBS was applied to each well o f a slide. The 
slides were incubated in a moist chamber at 37° C for 20 minutes. The slides were then washed for 
3 minutes in PBS and for 1 min in water and then dried. Ten microlitres o f flourescencein-labelled 
anti-mouse IgG conjugate diluted 1/40 with PBS containing Evans blue as a counterstain were 
applied to each well and the slides were incubated at 37°C for 20 min in a moist chamber. The slides 
were washed as previous, dried, mounted with glycerol mounting fluid and coverslipped. The slides 
were read using a Nikon ultraviolet light microscope (Nikon Inc. Instrumental Group, Garden City, 
USA) and photographed. The cells were monitored daily until 80% infectivity was achieved. The 
cells were then harvested for protein purification.
2.5.2.2. Western blot
Sf9 cells infected with AcNPV and BacCCHF-1 were propagated in T25 tissue culture flasks for 6 
days. Antigen spot slides were performed as described in section 2.5.2.1. to confirm expression of 
CCHF protein from BacCCHF-1 infected cells. Protein was purified from the Sf9 cells as described 
in section 2.5.3. below and cell lysates stored at -70° C. Prior to use, 50/^1 of each sample were boiled 
in 50//1 of IX SDS electrophoresis loading buffer (Maniatis et a/.,1982)(Appendix A) for 5 minutes 
at 100° C and proteins resolved using SDS-polyacrylamide gel electrophoresis methods. 
Polyacrylamide gel electrophoresis was performed in 1.5 mm thick slab gels using a 4% stacking gel 
and a 10% resolving gel in Tris-glycine buffer system overnight (Appendix A). Protein molecular 
weight determinations were made by comparison of bands with a known protein molecular weight 
marker (Roche Diagnostics).
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After electrophoresis was completed, the gel was equilibrated for 10 minutes in transfer buffer 
(Appendix A). A polyvinylidene diflouride (PVDF)(Roche Diagnostics) membrane was soaked in 
methanol for few seconds and then submerged in transfer buffer (Appendix A) for 3 minutes. 
Proteins were transferred onto the PVDF membrane using a Trans-Blot Semi-Dry Electrophoretic 
Transfer Cell (Biorad, California, USA) for 4 hours at 40 volts. The gels were stained with Coomasie 
blue (Appendix A) after transfer to confirm that the proteins had been transferred to the membrane. 
Initially the gels were stained after. To visualise the protein molecular weight marker, the lane on the 
membrane in which the molecular weight marker was run, was cut off and stained in Ponceau S 
solution (Appendix A). After visualizing by staining, the protein bands were marked for permanent 
record. CCHF specific proteins were reacted with anti-CCHF HMAF as the primary antibody and 
detected using the BM Chromogenic Western Blotting Kit (Roche Diagnostics) according to 
accompanying instructions. Briefly, the membrane was washed twice with in Tris-buffered saline 
(TBS)(Appendix A) and non-specific binding o f antibody was blocked by incubating the membrane 
for 30 minutes in 1% blocking solution (Appendix A). The membrane was then incubated with the 
primary polyclonal antibody, anti-CCHF HMAF fluid, diluted 1 /1000 in blocking solution. Following 
overnight incubation, the membrane was washed 4 times in TBS buffer containing 0.1% Tween 20 
for 10 minutes. Antibody was detected using anti-mouse IgG alkaline phosphatase diluted to 800 
mU/ml in 1% blocking solution. After 3 hours incubation, the membrane was washed 4 times for 
15 minutes as before. Finally, the colour reaction was initiated by the addition o f NBT/X phosphate 
substrate and the membrane incubated at room temperature with no agitation.
2.5.3. Purification of expressed proteins
The infected Sf9 cells grown in T25 tissue culture flask were harvested on day7 when the infectivity 
was approximately 80%, as determined by daily IF tests, centrifuged at 3000x g for 10 minutes and 
the supernatant stored at -20° C for use as inoculum. A crude cell lysate technique is a suitable 
method for purifying the antigen. The cells were lysed in 2.5 ml of NET/BSA (Appendix A), 
incubated on ice for 30 minutes and centrifuged at 3000x g for 10 minutes. To the cytosol fraction 
0.1% of SDS was added and the mix sonicated for 10 minutes. To the nuclear fraction, 2.5 ml of 
NET/BSA containing 0.1% of SDS was added and the mix sonicated for 10 minutes. For the
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following study the cytosol fraction of the protein was used and the nuclear fraction discarded 
because it formed insoluble pellets. The recombinant protein was aliquoted and stored at -20 °C. For 
the development o f the ELISA the optimal dilution o f antigen is determined by checkerboard 
titrations which must be performed for each batch of antigen prepared.
2.6. Enzyme-linked immunoassay
The ELISA were performed in 96 well immunoassay plates (Maxisorp, Nunc, Roskilde, Denmark), 
and unless otherwise stated reagent volumes of 100/^1 were used, the diluent for reagents was PBS 
containing 2% skimmed milk, incubations were performed for 1 hour at 37°C, wells were post- 
coated with 200//1 PBS containing 10% skimmed milk and plates were washed thrice with PBS 
containing 0.1% Tween 20. The optimal working dilution of reagents, including the sucrose acetone 
extracted antigen, were determined by chessboard titration.
2.6.1. Evaluation of recombinant antigens
Recombinant antigens, which included the nucleocapsid protein expressed by the BacCCHFl and 
the three recombinant proteins supplied by CDC, were evaluated using a sandwich ELISA. The plates 
were coated overnight at 4° C with monoclonal antibody 5G2 diluted 1/2000 in PBS. After post­
coating, each recombinant antigen was added to duplicate wells in 2-fold dilutions from 1/50, the 
plates were incubated, washed and reference positive test serum and negative control serum were 
added to the replicate wells at a dilution o f 1/100. The plates were incubated, washed and anti-human 
IgG HRPO conjugate (Zymed Laboratories Inc., San Franscisco, CA.USA) diluted 1/2000 was added, 
and the plates incubated. After further washing, the substrate, azino-di-(3-ethyl-benzthiazoline-6- 
sulfonate) (ABTS) (Kirkgaard and Perry Laboratories, Gaithersburg, Md, USA) was added and the 
plates incubated at room temperature (22 °C) for 30 minutes in the dark. The results were determined 
by reading the optical density (OD) at 402 nm on a Multiscan spectrophotometer (Flow Laboratories 
Inc., McLean, VA, USA). A positive result was recorded for OD values greater than twice the OD 
of the known negative serum at a dilution of 1/100. Optimal dilutions of antigen for use in the routine 
ELISA were determined in chessboard titrations and recorded as the highest dilutions of antigen 
which produced a positive result with positive control serum, without a non-specific reaction with
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negative control serum (OD <0.200 with negative serum).
2.6.2. IgM-capture ELISA
Plates were coated overnight at 4°C with /i-chain specific anti-human or anti-sheep IgM (Zymed 
Laboratories) diluted 1/1000 in PBS. After the plates were washed, human or sheep test sera were 
added to duplicate wells in 4-fold dilutions from 1/100 upwards. The plates were incubated, washed, 
and test or negative control antigen added at optimal dilution (1/800 for sucrose acetone test and 
negative control antigens, or 1/50 for recombinant antigen) to the replicate wells. After incubation, 
the plate was washed, anti-CCHF HMAF diluted 1/1000 added to the wells and the plates were 
incubated. After incubation and washing, anti-mouse HRPO conjugate (Zymed Laboratories), diluted 
1/2000, was added to the wells and the plates were incubated. After further washing, the substrate, 
ABTS, was added and the plates incubated at room temperature (22°C) for 30 minutes in the dark, 
and OD recorded as above. Net OD values were calculated by subtracting the OD reading with 
control antigen for each serum dilution from the OD reading with test antigen. Net OD values of 
> 0.400 recorded as positive reactions, and the antibody titre o f a serum was recorded as the reciprocal 
of the highest dilution producing a positive reaction. From statistical analysis of the results o f tests 
on large numbers of sera at CDC and in the SPU it has been established that only sera with titres of 
>400 can be interpreted as positive for antibody to CCHF virus (unpublished laboratory records). 
Reactions which occur only at the lowest 4-fold dilution of serum tested, 1/100, are rated as 
equivocal.
2.6.3. IgG sandwich ELISA
The presence of IgG antibody was demonstrated by sandwich ELISA. Plates were coated overnight 
at 4°C with monoclonal antibody 5G2 diluted 1/2000 in PBS. After post-coating, test or negative 
control antigen added at optimal dilution (1/1000 for sucrose acetone test and negative control 
antigens, or 1/100 for recombinant antigen) to replicate wells. The plates were incubated, washed and 
human or sheep test sera were added in 4-fold dilutions from 1/100 upwards to test and control 
antigen wells. The plates were incubated, washed and anti-human or anti-sheep IgG HRPO conjugate 
(Zymed Laboratories) was added at a dilution of 1 /2000. After further incubation and washing, ABTS 
substrate was added, allowed to react and results recorded and interpreted as above.
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2.6.4. Competitive ELISA
Total antibody activity in human, ostrich and small mammal sera was determined in a competitive 
ELISA (CELISA) in which test sera competed with coating antibody for binding of antigen, with 
immobilized antigen being detected by anti-CCHF HRPO conjugate. Plates were coated overnight 
at 4°C with monoclonal antibody, 5G2, diluted 1/8000. After post-coating, 50/ft of test serum was 
added to duplicate wells in doubling dilutions from 1/10 upwards, along with 50 /ft of test or negative 
control antigen added at optimal dilution (1/400 for sucrose acetone test and negative control 
antigens, or 1/50 for recombinant antigen). The plates were incubated for 3 hours at 37°C with 
mixing at 30 minutes intervals. After washing, anti-CCHF HRPO conjugate (prepared as described 
in section 2.2) was added to the wells at a dilution of 1/1000, the plates were incubated, washed, and 
reactions detected with ABTS substrate as described above. The CELISA produces much lower titres 
than the IgM-capture or the IgG sandwich ELISA, and the sera were recorded as positive if  the 
optical density reading was <50% of that produced by negative control serum at the lowest dilution 
tested, 1/10.
2.6.5 Calculation of sensitivity and specificity of serological tests with recombinant antigen
For purposes of calculating the sensitivity and specificity of tests for antibody to CCHF virus using 
recombinant antigen, the tests using sucrose acetone antigen were regarded as reference techniques 
which produced true positive and true negative results. By comparison, the results produced for the 
same samples in tests with recombinant antigen were rated as true or false positive results, and true 
or false negative results. The sensitivity of the tests with recombinant antigen were then calculated 
as: True positives/(True positives + False negatives) x 100 (Galen and Gambino, 1975).
The specificity o f the tests with recombinant antigen were calculated as:
True negatives/(True negatives + False positives) x 100 (Galen and Gambino, 1975).
2.7. Antigenic specificity testing of CCHF recombinant antigen
To determine the antigenic specificity o f the recombinant CCHF nucleocapsid protein in ELISA, the 
antigen was reacted with sera from guinea pigs hyperimmunised against three other nairoviruses: 
Dugbe, Hazara and Nairobi sheep disease. An IgG sandwich ELISA was performed as described in
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section 2.6.3. using anti-guinea pig HRPO (Zymed) diluted 1/2000.
2.8. Stability testing of recombinant antigen
Aliquots of recombinant antigen were incubated at different temperatures to determine the stability 
of the protein. The aliquots were left at room temperature (22°C), 37°C, 4°C, and their potency 
tested at two week intervals for 5 months by ELISA as described in 2.6.1 above. To determine the 
effect of freeze drying on the protein, 0.5ml aliquots were freeze dried and tested after reconstitution.
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3.0 Results
3.1. Preparation of CCHF baculovirus
The pBluebac baculovirus transfer plasmid containing the 1510 base pairs CCHF virus insert was 
isolated and digested with Nhe I restriction enzyme (GibcoBRL). The products were separated by 
electrophoresis using a 0.8% agarose gel and the 1510 base pairs CCHF virus insert was excised from 
the gel (Figure 2) and subjected to purification and ligation with the pFastBacl plasmid vector. 
Figure 2 shows undigested pBluebac transfer vector plasmid which is approximately 9000 base pairs 
and after digestion with Nhe I, the CCHF insert of approximately 1510 base pairs. The insert was 
then cloned into the pFastBac 1 plasmid. The ligated DNA was transformed into the DH5« 
competent cells. After 24 hours, the confirmed white colonies were picked, grown and the DNA 
isolated from the cells after 24 hours. The transformed DNA was isolated and analysed by 
electrophoresis. Figure 3 shows a DNA fragment of approximately 20 000 base pairs which confirms 
the presence of the transformed DNA in the preparation. Figure 4 shows the PCR product obtained 
after amplification o f the DNA with CCHF specific primers F2 and R3. The primers amplify a 536 
base pair region of the nucleocasid gene confirming the insertion of the CCHF S segment. Since the 
transformed DNA from the DH5« competent cells was shown by PCR to contain the CCHF insert, 
the DNA was transformed into the DHlOBac competent cells. The white colonies obtained from the 
transformation into the DH1 OBac competent cells were picked and grown in LB broth and the bacmid 
DNA isolated after 24 hours. To confirm the presence o f Bacmid DNA an aliquot was visualised by 
electrophoresis and a DNA band o f approximately 23 000 base pairs was identified as illustrated in 
Figure 5. However repeated attempts to show that transformation had occurred using pUC/M13 
primers and PCR as described in Section 2.4.5. were unsuccessful and the preparation was 
abandoned.
3.2. In  v itro  expression of CCHF recombinant protein
The expression of the CCHF recombinant protein in cell culture was detected by IF test and a 
Western blot was performed to confirm that the specific CCHF protein of the predicted size was 
expressed. Cells harvested from flasks infected with BacCCHFl on day six after inoculation were 
positive for CCHF antigen using IF as shown in Figure 6. Negative control slides prepared using 
cells infected with wild type showed no fluorescence (not shown). The Western blot (Figure 7)
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showed an expressed protein of approximately 50 kDa that reacted with mouse anti-CCHF HMAF 
fluid. Only recombinant protein expressed by cells infected with BacCCHF 1 and sucrose acetone 
antigen reacted with anti-CCHF antibody in Western blots. A larger band of approximately 97 000 
base pairs present in lane 2 is probably CCHF glycoprotein. The nucleocapsid protein in lane 2 is 
very faint but was present.
Figure 2. Agarose gel analysis o f pBluebac DNA. Lane 1: DNA Marker III fragments. Lane 2 and 
3: Undigested pBluebac DNA. Lane 4 and 5: Digested pBluebac DNA showing the 1510 bp CCHF 
insert. Lane 6: DNA Marker II fragments. Fragment sizes for the molecular weight markers are 
shown on the left and right of the figure.
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Figure 3. Agarose gel analysis o f transformed DNA isolated from the DH5« cells. Lane 1: DNA 
Marker III fragment. Lane 2: Transformed DNA. Fragments sizes for the molecular weight marker 
are shown on the left o f the figure.
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Figure 4. Agarose gel analysis of PCR products from transformed DNA isolated from DH5« cells 
and controls. Lane 1: DNA Marker III fragments. Lane 2: 536 base pair amplicon, CCHF positive 
control. Lane 3 ,4 ,5 :5 3 6  base pair product amplified from transformed DNA. Lane 6 and 7 :negative 
controls. Lane 8: DNA Marker VI fragments. Fragments sizes for the molecular weight markers are 
shown on the left and right of the figure.
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Figure 5. Agarose gel analysis of Bacmid DNA isolated from DH10 cells. Lane 1: DNA marker II 
fragments. Lane 2: DNA marker EH fragments. Lanes 3, 4, 5: Bacmid DNA. Fragment sizes for 
molecular weight marker II shown on left o f figure.
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Figure 6. Detection of expressed CCHF virus nucleoprotein from CCHF infected Sf9 cells using 
immunoflourescence.
Figure 7. Western blot to demonstrate expressed CCHF nucleocapsid protein by recombinant 
baculovirus. Lane 1: molecular weight marker. Lane 2: recombinant antigen. Lane 3: sucrose acetone 
extracted antigen. Lane 4: cell lysate. Lane 5: control AcNPV
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3.3. Antigenic reactivity of recombinant proteins
Only the recombinant protein expressed by the baculovirus BacCCHF 1 supplied by US AMRIID was 
found to react satisfactorily with reference CCHF antibody in ELISA titrations. The three 
recombinant proteins supplied by CDC showed weak activity in the ELISA, lower dilutions of these 
antigens gave non-specific reactions and hence the proteins were excluded from the study at this 
point as being unsuitable for use as diagnostic antigens.
The optimal dilution of sucrose acetone extracted antigen as determined in chessboard titration was 
1/800 for use in the IgM-capture ELISA, 1/1000 for use in the IgG sandwich ELISA, and 1/400 for 
use in the CELISA, while the optimal dilution o f the BacCCHF 1 recombinant antigen was 1/50 for 
use in the IgM-capture ELISA, 1/100 for the IgG sandwich ELISA, and 1/50 for the CELISA
Although only sera which react positively in IgM and IgG ELISA at dilutions > 1/400 are interpreted 
as being positive for antibody to CCHF virus (See Materials and methods section 2.6.2), all serum 
reactions detected in the present study, including equivocal reactions (which are positive only at the 
lowest 4-fold dilution of serum tested, 1/100), are reported in sections 3.4 1-3.4.2 and 3.5.1-3.5.2 
below, and in Figures 8,9, and 11-16, plus Appendices B-E, and H-M. However, only IgM and IgG 
ELISA reactions interpreted as positive (with titres >400) are used in calculating the sensitivity and 
specificity of recombinant antigen in relation to sucrose acetone extracted antigen (Section 3.8 
below). In contrast, antibody titres detected in the CELISA are lower than those detected in the IgM 
and IgG ELISA, and positive reactions recorded at the lowest dilution of serum tested, 1/10, are 
interpreted as positive for antibody to CCHF virus (See Materials and methods section 2.6.4). 
Published literature showed higher titres than some recorded in this study. One explanation could be 
that the sera have been frozen and thawed for a number of related studies which could be responsible 
for the drop in antibody titre (Burt et al., 1994).
3.4. Detection of antibody response to CCHF virus infection in human sera
3.4.1. IgM detection by ELISA using sucrose acetone extracted antigen
The 135 serum samples of confirmed CCHF patients included in the study were collected from day 
5 to one year after the onset of illness as shown in Figure 1. The results of IgM-capture ELISA for 
detection of antibody to CCHF virus are summarised in Figure 8A, and the titres recorded for
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individual serum samples are shown in Appendix B.
No IgM antibody was detected in the earliest serum sample available for testing which was collected 
on day 5 after the onset of illness. An IgM antibody response was detected in only 2/3 serum samples 
collected on day 6, while 5/6 sera were positive on day 7, and 5/ 7 were positive on day 8. By day 9 
after the onset o f illness all o f the serum samples were positive for IgM antibody, although only 15/16 
serum samples were positive on day 10. All serum samples were positive for IgM antibody from day 
11 to day 21. One month after the onset o f illness there were still 15/19 positive serum samples, while 
the only serum analysed on month 2 was also positive. Thereafter the proportion of positive sera 
declined steadily and all of the samples analysed 8 months after the onset of illness were negative for 
IgM antibody, and only isolated positive reactions were recorded after that (Figure 8A). The 
maximum titre was 6400, and titres started to decline from the first month after the onset of illness.
3.4.2. IgM detection by ELISA using recombinant antigen
The results obtained in the IgM-capture ELISA using recombinant antigen on the 135 CCHF patient 
sera were similar to those reported above for sucrose acetone extracted antigen, and are summarised 
in Figure 8B, while the titres recorded for individual sera are shown in Appendix C.
The serum sample taken on day 5 after the onset of illness was negative for IgM antibody. On day 
6 there were 2/3 sera IgM antibody positive, on day 7 there were 4/6 positive sera, 4/7 were positive 
on day 8, and by day 10 after the onset o f illness 15/16 serum samples were positive for IgM antibody 
to CCHF virus. From day 11-21 all of the serum samples had demonstrable IgM antibody. One month 
after the onset of illness 14/19 serum samples were still positive and then the proportion of positive 
sera declined steadily until all samples analysed at 8 and 9 months were negative, and only isolated 
positive reactions were recorded after that (Figure 8B). The maximum titre attained was 6400 and 
levels started to decline steadily after the first month.
3.4.3. IgG detection by ELISA using sucrose acetone extracted antigen
The results obtained for IgG antibody detection by ELISA using sucrose acetone antigen on the 135 
sera from CCHF patients are summarised in Figure 9A, and the titres are recorded in Appendix D.
39
No antibody was detected in the earliest serum samples available for testing which were collected 
from day 5 and 6 after the onset o f illness. Antibody was detected in 3/6 sera on day 7, and 2/7 were 
positive on day 8, while on day 8 after the onset of illness 6/7 were positive. By day 10 15/16 serum 
sample were positive, and from day 11 to first the year after the onset o f illness, all serum samples 
showed demonstrable IgG antibody response except for the seventh month when there was one 
negative serum. The maximum titre attained was 6400.
3.4.4. IgG detection by ELISA using recombinant antigen
Serological results obtained from the IgG sandwich ELISA using recombinant antigen on 135 CCHF 
patient sera were similar to those described using sucrose acetone extracted antigen, and are 
summarised in Figure 9B, while the titres are recorded in Appendix E.
The serum samples collected on day 5 and 6 were negative for IgG antibody. Antibody was 
demonstrable in 3/6 sera on day 7, in 1 /7 sera on day 8, in 6/7 sera on day 9, and by day 10 there were 
15/16 sera positive. All serum samples analysed from day 11 to the end o f the first year were positive 
except one from month 7. This serum was negative by ELISA using both sucrose acetone antigen and 
recombinant antigen, and was negative for antibody to CCHF using IF (laboratory results) and this 
was probably due to an individual response. The maximum titre attained was 6400.
3.4.5. CELISA using the sucrose acetone extracted antigen
The results obtained for total antibody detection by CELISA using sucrose acetone antigen on the 
135 CCHF patient sera are summarised in Figure 10A, and the titres are recorded in Appendix F. The 
total antibody response detected using sucrose acetone extracted antigen was demonstrable at the 
earliest in 4/6 serum samples collected on day 7 after the onset of illness. On day 8 there were 4/7 
rising to 12/18 on day twelve. From day 15-23 all serum samples were positive except the only 
available serum sample from the seventh month.
3.4.6. CELISA using the recombinant antigen
The results obtained in CELISA using recombinant antigen for the detection o f total antibody activity 
in CCHF patient sera are summarised in Figure 10B, and the titres are recorded in Appendix G. 
Antibody was detected in 1/3 sera on day 6. On day 7,4/6 serum samples were positive, 4/7 on day
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8, 6/7 on day 9, 14/16 on day 10, rising to 16/18 on day 12. From day 15 all samples were positive 
until the end of the first year except for the single sample available for the seventh month.
3.4.7. Control panel of negative sera
A total of 160 sera from known non-CCHF patients were tested for IgG, IgM and total antibody to 
CCHF using ELISA with both antigens and CELISA. All the sera were screened at a dilution of 
1:100 and were antibody negative. The results for the optical density values obtained are presented 
in Appendix H.
3.5. Detection of antibody response to CCHF virus in experimentally infected sheep
3.5.1. IgM ELISA using sucrose acetone extracted and recombinant antigens
The antibody responses to CCFIF virus detected by IgM-capture ELISA using sucrose acetone and 
recombinant antigens on 63 serum samples collected from day 0 to month 8 post-infection from three 
experimentally inoculated sheep designated 92,48 and 37, are presented graphically in Figures 11-13, 
and the titres are recorded in Appendices I-K.
There was no detectable IgM antibody to CCHF virus in sera collected from sheep 92 from day 0-6 
post-inoculation when using the sucrose acetone extracted antigen as illustrated in Figure 11 A. 
Antibody was detected in sera collected on days 7-28, but from month 5-8 IgM antibody tests were 
again negative with sucrose acetone extracted antigen. Similar results were obtained with 
recombinant antigen (Figure 1 IB).
The serum samples collected from sheep 48, showed no demonstrable IgM antibody from day 0-6 
post-inoculation in tests using the sucrose acetone antigen, as illustrated in Figure 12A. IgM 
antibody was demonstrable from day 7-21, and not after that. Similar esults were obtained with 
recombinant antigen (Figure 12B).
Antibody was detected from day 4-14 post-inoculation in sheep 37 using sucrose acetone antigen, 
as illustrated in Figure 13 A, and after that no IgM antibody was detectable The results o f tests with 
recombinant antigen for the detection o f IgM antibody were negative on days 0-3 post-inoculation, 
and positive from day 4-14. After that there was no demonstrable IgM antibody activity (Figure 13B).
41
A
nt
ib
od
y 
lo
g1
0 -
4 T
A
0 2 4 6 8 10 12 14 16 1820 1 3 5 7 9 1
Days Months Year
Figure 8. IgM antibody level to CCHF in human serum samples collected on different days after
the onset of illness, detected by IgM-capture ELISA using sucrose acetone-extracted antigen (A)
and recombinant antigen (B).
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Figure 9. IgG antibody level to CCHF in human serum samples collected on different days after
the onset o f illness, detected by IgG sandwich ELISA using sucrose acetone extracted antigen (A)
and recombinant antigen (B).
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Figure 10. Total antibody level to CCHF virus in human serum samples collected on different days
after the onset of illness, detected by CELISA using sucrose acetone extracted antigen (A) and
recombinant antigen (B).
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3.5.2. IgG ELISA using sucrose acetone extracted and recombinant antigens
The results of IgG antibody tests on the three experimentally infected sheep using sucrose acetone 
extracted and recombinant antigens are presented graphically in Figures 14-16, and the titres are 
recorded in Appendices L-N.
For sheep 92, IgG antibody response was detected from day 7 post-inoculation up until month 8, the 
last serum available, when using the sucrose acetone extracted antigen (Figure 14A) and similar 
results were obtained with recombinant antigen (Figure 14B).
In tests with sucrose acetone extracted antigen the serum samples o f sheep 48 showed IgG antibody 
response from day 7 post-inoculation up to month 8, except for a negative result on the month 7 
sample (Figure 15A). In tests with the recombinant antigen similar results were obtained (Figure 
15B).
Serum samples collected from sheep 37 showed demonstrable IgG antibody from day 5 until month 
8 using sucrose acetone extracted antigen (Figure 16A). Similar results were obtained with 
recombinant antigen (Figure 16B).
3.6. Detection of CCHF antibody in ostrich sera
A total of 271 ostrich sera submitted to SPU for screening for antibody to CCHF virus as a 
prerequisite to export were tested by CELISA using sucrose acetone extracted antigen, and with 
recombinant antigen for comparison. The sera were screened at a single dilution of 1/10 to produce 
a positive or negative result, and were not titrated to end-point. The results are shown in Table 1.
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Figure 11. IgM antibody log titre to CCHF virus in relation to day after infection as demonstrated
by IgM capture ELISA using sucrose acetone antigen (A) and recombinant antigen (B), in serum
samples from experimentally infected sheep number 92.
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Figure 12. IgM antibody log titre to CCHF virus in relation to day after infection as detected by
IgM capture ELISA using sucrose acetone antigen (A) and recombinant antigen (B), in serum
samples from experimentally infected sheep number 48.
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Figure 13. IgM antibody log titre to CCHF virus in relation to day after infection as detected by
IgM capture ELISA using sucrose-acetone extracted antigen (A) and recombinant antigen (B), in
serum samples from experimentally infected sheep number 37.
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Figure 14. IgG antibody log titre to CCHF virus in relation to day after infection as detected by
IgG sandwich ELISA using sucrose acetone extracted antigen (A) and recombinant antigen (B),
in serum samples from experimentally infected sheep number 92.
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Figure 15. IgG antibody log titre in relation to day after infection as detected by IgG sandwich 
ELISA using sucrose acetone extracted antigen (A) and recombinant antigen (B), in serum 
samples from experimentally infected sheep number 48.
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Figure 16. IgG antibody log titre to CCHF virus in relation to day after infection as detected by
IgG sandwich ELISA using sucrose acetone extracted antigen (A) and recombinant antigen (B),
in serum samples from experimentally infected sheep number 37.
51
Table 1. Results of screening tests for antibody activity to CCHF virus performed on 271 
ostrich serum samples by CELISA using sucrose acetone extracted antigen in comparison with 
recombinant antigen.
Recombinant antisen
Sucrose acetone extracted antisen Positive Nesative
Positive 14 2
Negative 0 255
3.7. Detection of antibody by CELISA in experimentally infected small mammals
The antibody response to CCHF virus in 35 serum samples collected from small mammals at the 
indicated intervals after experimental infection, was detected by CELISA using sucrose acetone 
extracted antigen in comparison with recombinant antigen (Table 2).
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Table 2. T otal antibody titres in the sera of small mammals experimentally infected with CCHF 
virus as detected by CELISA using sucrose acetone extracted and recombinant antigens, shown 
in relation to day after inoculation.
sucrose acetone
extracted antigen Recombinant antigen
Day____________ Species__________ Animal number_______Antibody titre__________ Antibody titre
Mystromys albicaudatus
1 1 0 0
1 2 0 0
1 3 0 0
1 4 0 0
14 1 20 20
14 2 40 20
21 1 160 160
21 2 80 40
21 3 20 20
28 1 0 80
28 2 160 80
28 3 40 80
U n reco rd ed 2 0 160
U n reco rd ed 3 160 160
U n reco rd ed 4 160 160
Tatera brantsii
1 1 0 0
1 2 0 0
1 3 0 0
21 1 0 0
21 2 160 80
35 1 20 20
35 2 20 20
35 3 80 160
Tatera leucogaster
1 2 0 0
1 4 0 0
2 4 0 0
3 1 0 0
28 1 80 20
28 2 160 80
28 3 80 80
Aethomys namaquensis
1 1 0 0
1 2 0 0
14 1 20 20
14 2 0 0
14 3 0 0
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3.8 Sensitivity and specificity of serological tests with recombinant antigen
3.8.1 IgM-capture ELISA on CCHF patient sera
The results obtained on 295 serum samples from confirmed CCHF patients in IgM capture ELISA 
with sucrose acetone extracted and recombinant antigens (Appendices B, C and H) were interpreted 
as positive (titres >400) or negative (titres <400), and the totals are shown in Table 3.
In addition to 160 sera from non-CCHF patients there were 135 sera from confirmed patients, of 
which not all would show a demonstrable antibody response. One would expect a negative result 
from sera collected early after onset of illness and in the case of IgM antibody, sera collected a month 
after onset as IgM is no longer detected after a few weeks. Hence the number of true positives 
indicated in the following calculations for each ELISA reflect number of antibody positive specimens 
using the reference ELISA, in this case the ELISA using sucrose acetone antigen. The true negatives 
include the sera from non-CCHF patients and samples from CCHF patients that were negative using 
the reference ELISA.
Table 3. Summary of the results obtained on 295 serum samples from confirmed CCHF 
patients in IgM capture ELISA with sucrose acetone extracted and recombinant antigens 
(antibody titres >400 interpreted as positive results).
Recombinant antigen
Sucrose acetone extracted antigen Positive Negative
Positive 104 6
Negative 0 185
As described in Materials and methods (Section 2..6.5), tests using sucrose acetone antigen are 
regarded as reference techniques which produce true positive and true negative results. By 
comparison, the results produced in tests with recombinant antigen are rated as true or false positive 
results, and true or false negative results. The sensitivity o f the test with recombinant antigen is then 
calculated as:
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True positives/(True positives + False negatives) x 100 
In the present instance = 104/110 x 100 = 94.5%
The specificity of the tests with recombinant antigen were calculated as:
True negatives/(True negatives + False positives) x 100 (Galen and Gambino, 1975).
In the present instance =185/185 x 100 = 100%
3.8.2 IgG sandwich ELISA on CCHF patient sera
The results obtained on 295 serum samples from confirmed CCHF patients in IgG sandwich ELISA 
with sucrose acetone extracted and recombinant antigens (Appendices D, E and H) were interpreted 
as positive (titres >400) or negative (titres <400), and the totals are shown in Table 4.
Table 4. Summary of the results obtained on 295 serum samples from confirmed CCHF 
patients in IgGsandwich FLISA with sucrose acetone extracted and recombinant antigens 
(antibody titres >400 interpreted as positive results).
Recombinant antigen
Sucrose acetone extracted antigen Positive Negative
Positive 115 5
Negative 3 172
The sensitivity of the test with recombinant antigen is: 115/120 x 100 = 95.8% 
The specificity of the tests with recombinant antigen is: 172/175 x 100 = 98.3%
3.8.3 CELISA on CCHF patient sera
The results obtained on 295 serum samples from confirmed CCHF patients in CELISA with sucrose 
acetone extracted and recombinant antigens (Appendices F, G and H) are summarised in Table 5
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(titres > 10 are recorded as positive).
Table 5. Summary of the results obtained on 295 serum samples from confirmed CCHF 
patients in CELISA with sucrose acetone extracted and recombinant antigens (titres >10 are 
recorded as positive).
Recombinant antisen
Sucrose acetone extracted antisen Positive Nesative
Positive 97 8
Negative 14 176
The sensitivity of the test with recombinant antigen is: 97/105 x 100 = 92.4%
The specificity o f the tests with recombinant antigen is: 176/190 x 100 = 92.6%
3.8.4 IgM-capture ELISA on experimentally infected sheep sera
The results obtained on 63 serum samples from 3 sheep experimentally infected with CCHF virus 
in IgM capture ELISA with sucrose acetone extracted and recombinant antigens (Appendices I, J and 
K) were interpreted as positive (titres >400) or negative (titres <400), and the totals are shown in 
Table 6.
Table 6. Summary of the results obtained on 63 serum samples from 3 sheep infected with 
CCHF virus in IgM capture ELISA with sucrose acetone extracted and recombinant antigens 
(antibody titres >400 interpreted as positive results).
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Recombinant antigen
Sucrose acetone extracted antisen Positive Neeative
Positive 23 5
Negative 0 35
The sensitivity of the test with recombinant antigen is: 23/28 x 100 = 82.1%
The specificity of the tests with recombinant antigen is: 35/35 x 100 = 100%
3.8.5.IgG sandwich ELISA on experimentally infected sheep sera
The results obtained on 63 serum samples from 3 sheep experimentally infected with CCHF virus 
in IgG sandwich ELISA with sucrose acetone extracted and recombinant antigens (Appendices L, 
M and N) were interpreted as positive (titres >400) or negative (titres <400), and the totals are shown 
in Table 7.
Table 7. Summary of the results obtained on 63 serum samples from 3 sheep infected with 
CCHF virus in IgG sandwich ELISA with sucrose acetone extracted and recombinant antigens 
(antibody titres >400 interpreted as positive results).
Recombinant antigen
Sucrose acetone extracted antigen Positive Negative
Positive 26 4
Negative 1 31
The sensitivity of the test with recombinant antigen is: 26/30 x 100 = 86.7%
The specificity of the tests with recombinant antigen is: 31/32 x 100 = 96.9%
3.8.6 CELISA on ostrich sera
The results obtained on 271 ostrich serum samples in CELISA screening tests with sucrose acetone 
extracted and recombinant antigens are summarised in Table 1 above (Section 3.6) (titres > 10 are 
recorded as positive).
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The sensitivity o f the test with recombinant antigen is: 14/16 x 100 -  87.5%
The specificity of the tests with recombinant antigen is: 255/255 x 100 = 100%
3.8.7 CELISA on experimentally infected small mammal sera
The results obtained on 35 serum samples from small mammals experimentally infected with CCHF 
virus in CELISA with sucrose acetone extracted and recombinant antigens (Table 2) are summarised 
in Table 8 (titres > 10 are recorded as positive).
Table 8. Summary of the results obtained on 35 serum samples from small mammals 
experimentally infected with CCHF virus in CELISA with sucrose acetone extracted and 
recombinant antigens (titres ^10 are recorded as positive). (The full results are presented in 
Table 2.)
Recombinant antieen
Sucrose acetone extracted antieen Positive Neeative
Positive 17 0
Negative 2 16
The sensitivity of the test with recombinant antigen is: 17/17 x 100 = 100%
The specificity of the tests with recombinant antigen is: 16/18 x 100 = 88.8%
3.9. Antigenic specificity of CCHF recombinant antigen
The antigenic specificity o f the recombinant CCHF nucleocapsid protein purified protein was 
determined in an IgG sandwich ELISA using guinea pig sera raised against other nairoviruses 
antigenically related to CCHF virus, namely, Dugbe, Hazara and Nairobi sheep disease (NSD) 
viruses. Guinea pig sera against Dugbe and Hazara viruses showed no reaction with the recombinant 
antigen. The serum against NSD virus reacted positively at a dilution o f 1/100 and was negative at 
1/400. Since specimens are routinely recorded as positive only if  reaction is present at 1/400, the 
weak reaction with the recombinant antigen would be recorded as equivocal or non-specific.
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3.10. Stability testing of CCHF recombinant antigen
Aliquots of recombinant antigen left at room temperature and at 37 °C lost activity after two weeks; 
the antigen left at room temperature had lost about 25% of activity and the one left at 37 °C lost about 
45%. By the end of the first month the aliquots left at room temperature had already lost about 75% 
of activity whilst antigen left at 37 °C had almost completely lost activity. The aliquots left at 4°C 
were stable up to the fifth month o f testing with <1% of activity lost. Freeze drying did not affect the 
activity of the recombinant antigen.
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4.0 Discussion
As mentioned in the introduction, CCHF is being recognized with increasing frequency as a cause 
o f illness in Africa, probably as a result of increased awareness o f the disease and the availability of 
a specific diagnostic service in South Africa (Swanepoel, 1998). The virus has the propensity to cause 
nosocomial infection, and hence rapid and accurate laboratory confirmation of the diagnosis is 
important to allow for timely isolation of the patient and the institution of barrier-nursing procedures 
for the protection o f health care personnel and the community at large, and also to allow for the 
institution of appropriate therapy for the patient. However, it has been the experience o f the SPU over 
the past 21 years that the vast majority o f suspected cases o f haemorrhagic fever, approximately 95%, 
prove to be severe cases of more common diseases, such as bacterial septicaemias, viral hepatitis or 
even malaria (unpublished laboratory records). Nevertheless, these false alarms can be extremely 
inconvenient and costly for hospitals since barrier-nursing is an expensive procedure to implement 
which frequently requires the emptying of wards in order to place patients in isolation, sometimes 
with resultant overloading of neighbouring medical facilities. In particular, the dedication o f a 
modern multi-bed intensive care ward, with highly trained staff and expensive equipment to the care 
of a single patient, can be extremely costly. Thus, it is almost equally important to eliminate false 
suspected cases of haemorrhagic fever rapidly as it is to confirm genuine cases.
Laboratory investigation o f CCHF is undertaken only in BSL4 laboratories, such as that operated by 
the SPU for South Africa. However, the virus is widely distributed in Africa, Eastern Europe and 
Asia, and in recent years the SPU has diagnosed cases of the disease or found serological evidence 
of the presence of the virus in several countries in Africa and in the Middle East, including Iraq, Iran, 
Afghanistan, and Pakistan (unpublished laboratory records). As mentioned in the Introduction many 
of these countries do not have the finances to build and maintain BSL4 laboratories o f their own, and 
the SPU has received several requests from health authorities in these countries, and even from 
Australia and the World Health Organization in Geneva, to be of assistance in developing safe 
diagnostic procedures which can be used in less established laboratories.
A diagnosis o f CCHF is generally confirmed in the laboratory by detection o f viral RNA amplified 
by RT-PCR, isolation of virus, demonstration of seroconversion or a >4-fold increase in antibody
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titre, or detection o f specific IgM antibody activity (Shepherd et al., 1986; Burt, et al., 1994; 1998) 
O f these techniques, the RT-PCR is more amenable to being performed safely than is the isolation 
of live virus, and this would probably suffice as a diagnostic technique if it could be supported by an 
antibody test using safe antigen, in particular an IgM test. In other words the RT-PCR can be 
performed safely outside a P4 laboratory on acute stage specimens in which antibody is not yet 
demonstrable. However after the acute stage, when viral nucleic acid is no longer present then an 
antibody test is required for convalescent phase sera in which an antibody response is demonstrable. 
In the instance of CCHF, these procedures could further be rendered safe through inactivating 
patients’ blood or serum samples at 60°C/30 min before testing since the infectivity o f the virus is 
thermolabile. An early publication on a limited number o f confirmed CCHF patients showed that 
ELISA was a suitable method for detection o f IgG amd IgM antibody to CCHF virus (Shepherd et 
al., 1989c). The use of ELISA was further investigated using a larger number of samples which 
showed that the ELISA yielded results in close agreement with the IF test for detection of an antibody 
response and provided evidence that the ELISA using a sucrose acetone antigen was a suitable gold 
standard or reference test for serodiagnosis (Burt et al., 1994). This study has now compared the 
ELISA using sucrose acetone antigen a potentially biohazardous antigen, with ELISA using a 
recombinant antigen based on the nucleocapsid protein of CCHF virus which is a non-infectious 
antigen.
A further demand for safe reagents for performing antibody tests has arisen from the requirement 
imposed by certain countries which are free of CCHF, notably countries in the European Union, that 
live animals o f susceptible species from countries where the virus is present should be free of 
antibody as a pre-requisite to importation. The requirement applies particularly to ostriches, and was 
imposed following an outbreak o f CCHF among workers in an ostrich abattoir in Oudsthoom, South 
Africa, in 1996 (Swanepoel et al., 1998). Since then the SPU has tested serum from large numbers 
of exported ostriches on behalf of farmers in South Africa and neighbouring states. Moreover, the 
birds are re-bled on arrival in Europe and serum sent back to SPU for re-testing. Similar restrictions 
are imposed on the international movement of certain zoo animals. It would be most convenient if 
importing and exporting countries could perform their own tests. Furthermore, many countries where 
the virus is known or suspected to be present wish to conduct serosurveys on livestock and wild 
animals in order to determine the prevalence of CCHF virus. For most domestic animal species
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anti-immunoglobulin peroxidase conjugates which permit ELISA to be performed with CCHF 
antigen are commercially available, and for the testing o f wild animal and ostrich sera for which no 
conjugates are available, the SPU developed the CELISA (Burt et al., 1993). Thus it is clear that safe 
antigen is needed for veterinary use in addition to the requirement for diagnosing human infections.
Recombinant antigens are being used more frequently as diagnostic antigens, and apart from safety 
they have the advantage that they reduce the use of laboratory animals since sucrose acetone extracted 
mouse brain is currently the most effective CCHF antigen. Monoclonal antibody studies have shown 
that the nucleocapsid is the most highly conserved viral protein (Blackburn et al., 1987), and it is 
therefore most useful for diagnostic assays. Recombinant antigens have previously been investigated 
as diagnostic tools for CCHF (Marriott et al., 1994). The investigators produced a full length 
nucleocapsid protein as well as three nucleoprotein-derived peptides from the cDNA of CCHF virus. 
Two of the peptides had poor antigenic reactivity, but the full length nucleoprotein and one o f the 
peptides had some potential for use as diagnostic tools since each of these two reagents reacted with 
6/8 known positive human sera. Full evaluation would require a larger collection of positive sera, and 
there does not appear to have been further development o f these antigens.
The failure o f the recombinant baculovirus produced in the present project to express antigenically 
active nucleoprotein is not surprising since this has seldom been achieved successfully, and indeed 
the inadequately antigenic recombinant nucleoprotein and peptides received from CDC were 
produced in an M.Sc. project in Atlanta. The 3 peptides showed even poorer reactivity than the 
baculovirus-expressed full length nucleoprotein, and this could be due to their method of expression 
as bacterial products, with incorrect folding or fusion of parts o f the structure that affect antigenicity 
(Morii et al., 1998). However, baculovirus BacCCHFl received from USAMRIID was found to 
express adequate quantities of nucleoprotein of suitable antigenic reactivity, which could be purified 
and evaluated against the comparatively large collection of sera available for the present study, 
including sera from confirmed human cases of CCHF, sera from experimentally infected sheep and 
small mammals, plus ostrich sera.
In the event, the nucleoprotein antigen prepared from BacCCHFl produced extremely promising 
results in comparison with the reference sucrose acetone extracted antigen, although the congruity
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of the results produced by the two antigens varied with the type o f test (IgG ELISA, IgM ELISA and 
CELISA), and with the species from which the sera were derived (human patients, sheep, small 
mammals and ostriches) (Appendices B-N and Tables 1-8). For example, the results obtained for 
human IgM antibody had a 94.5 % sensitivity and 100% specificity in comparison with the results 
obtained with sucrose acetone antigen, whereas the sensitivity was only 82.1 %, and specificity 100%, 
in the sheep IgM test (Sections 3.8.1 and 3.8.4). Similarly, sensitivity was relatively low in the ostrich 
CELISA (87.5%), and specificity in the small mammal CELISA (88.8%) (Sections 3.8.6 and 3.8.7). 
Nevertheless, all of the results obtained with the recombinant antigen lie within a range that should 
be amenable to relatively simple adjustment.
The sensitivity and specificity o f serological tests are adjusted by varying the concentrations of 
reagents or the test conditions, but primarily by adjusting the cut off values for positivity. In this 
regard it is notable that by simply dropping the cut off level for positivity from a titre of 400 to 100, 
the sensitivity and specificity of ELISA for IgM and IgG in sheep sera with recombinant antigen both 
become 100%, as can be seen readily from inspection o f Appendices I-N. In other words, there is 
complete congruity between results obtained in IgM and IgG tests on sheep sera with the two antigens 
if the cut off titre for positivity is adjusted to 100. However, the cut off titre o f400 used for IgM and 
IgG ELISA with sucrose acetone antigen is based on the analysis of results obtained on sera from 
hundreds of suspected and confirmed human cases of CCHF, and thousands o f sera from ostriches 
and sheep, including experimentally infected animals, tested by the SPU over a period o f years, and 
the value is calculated to retain adequate sensitivity while increasing specificity to the point where 
non-specific reactors in test populations are not recorded as false positives. It can be argued that for 
the purposes of the present study it would have been satisfactory to obtain large numbers o f randomly 
bled samples from human or livestock subjects, such as human blood donors, in order to perform the 
necessary tests to adjust cut off values. However, it is a common misconception that tests with known 
positive sera can be evaluated in comparison with random samples from general populations; in 
reality tests should be evaluated in the context of the syndrome under investigation (Galen and 
Gambino, 1975). This means that the definitive evaluation of the recombinant antigen for use in the 
diagnosis of the human disease will have to be achieved by prospectively using it on suspected cases 
of CCHF, the vast majority o f which can be expected to be false alarms on the basis of past 
experience. The present results serve to indicate that there is a sound basis for proceeding with such
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prospective evaluation of the recombinant antigen.
In the broad sense discussed above, specificity refers to the ability o f a test or antigen to avoid 
producing false positive reactions when applied to samples from a particular syndrome. Antigenic 
specificity forms a component o f this broader specificity; it is a measure o f whether or not the test 
or antigen is likely to produce false positive results when applied to serum from individuals infected 
with known antigenic relatives o f the pathogen under investigation. The antigenic specificity of the 
recombinant CCHF nucleocapsid antigen was assessed by performing ELISA with guinea pig sera 
raised against the closest known antigenic relatives o f CCHF virus, namely, the nairo viruses Hazara, 
Dugbe, and Nairobi sheep disease (NSD). Weak cross-reactivity was found only with with the NSD 
antiserum. However, extensive tests on human patient and livestock sera have previously indicated 
that the only nairovirus other than CCHF likely to be encountered in southern Africa is Dugbe virus, 
and this is likely to be restricted to locations where ticks o f the genus Amblyomma occur (Burt et al., 
1996).
The remarkable stability o f the recombinant antigen observed at 4°C bodes well for its use as a 
diagnostic antigen (Section 3.10). The antigen retained virtually all of its potency for 5 months at 
4°C, and this greatly exceeds the norm for commercially available ELISA reagents. Moreover, the 
stability of the antigen when subjected to freeze drying should facilitate distribution o f the reagent 
to other laboratories.
It can be concluded that there are good grounds for proceeding with further evaluation of the 
recombinant nucleoprotein antigen expressed by the baculovirus BacCCHFl, through using the 
antigen prospectively in parallel with sucrose acetone and/or cell culture derived antigens (which lack 
potency and stability) in ELISA on human and livestock specimens routinely received by the SPU 
and other institutions engaged in similar work on CCHF.
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Appendix A: Buffers, reagents, pbluebac restriction map
A. Preparation of Baculovirus
1. Isolation of pBluebac plasmid from E. co li
Lauria Bertani (LB) Broth. pH 7.5: 1% Bacto-tryptone
0.5% Bacto-Yeast extract 
1% NaCl
Lysosome solution: 2/ig/ml lysosome
50mM glucose 
lOmM EDTA 
25mM Tris-Cl, pH 8.0
Tris-EDTA (TE) buffer, pH 8.0: lOmM Tris
ImM EDTA
2. Restriction enzyme digest and recovery of DNA from the gel
Tris-acetate EDTA (TAE) buffer, pH 8.0: 0.04 M Tris-acetate
0.001 M EDTA
3. Dephosphorylation of the pFASTBac 1 vector
10X calf intestinal alkaline phophatase (CIP) buffer: 0.5M Tris -HC1
lOmM MgCl,
ImM ZnCl2
lOmM spermidine, pH 9.0
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10X Sodium-Tris-EDTA (STE) buffer, pH 8.0: lOOmM Tris-Cl
lM N aC l 
lOmM EDTA
4. Transformation of DH5a competent cells
Lauria Bertani (LB) agar: lOg Bactotryptone
5g Yeast extract 
lOg NaCl
12g Bacteriological agar
Stir to dissolve and autoclave. Cool to 55° C and add 50/ig/ml o f kanamycin sulphate, 10/ig/ml of 
tetracycline, 7/ig/ml o f gentamycin, 100/ig/ml o f Bluo-gal and 40 /ug/ml o f IPTG. Stir and pour to 
a plate.
S.O.C. medium: 2g Bactotryptone
0.55g Yeast extract 
lm l 1M NaCl 
lm l 1M KC1, pH 7.0
Autoclave and cool to 55° C, add 1 ml 2 M Mg++ (1 M MgCl2, 1 M M gS04) and add 1 ml o f glucose. 
Filter through a 0.2/^m filter unit.
5. Isolation o f recombinant bacmid DNA
Solution I: 15 mM Tris-Cl
10 mM EDTA 
100/^g/ml Rnase A, pH 8.0
Solution II: 0.2 N NaoH 
1% SDS
75
B. Purification of protein
NET/BSA: 150mMNaCl
5mM EDTA 
50mM Tris-HCl 
0.5% NP40 
lmg/ml BSA
0.1% sodium dodecyl sulphate (SDS)
C. Western blot
Acrylamide-bisacrylamide: Prepared in ratio 30:0.8 and stored in dark bottle
10X Electrophoresis bath buffer: 0.25M Tris-HCl, pH 8.3
1.92M glycine 
1% SDS
10% resolving gel: 1M Tris-HCl, pH 8.8
26.7 ml Acrylamide/bisacrylamide (30:0.8)
30 ml 1M Tris-HCl, pH 8.8
0.8 ml 10% SDS
18.5 ml distilled water
4 ml 1.% ammonium persulphate
20 fj.1 TEMED
4% stacking gel: 1M Tris-HCl, pH 6.8
2 ml Acrylamide/bisacrylamide (30:0.8)
1.9 ml 1M Tris-HCl, pH 6.8
0.15 ml 10% SDS
1 ml 80% glycerol
9.25 ml distilled water
0.7 ml 1.5% ammonium persulphate
20 fA TEMED
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0.06M Tris-HCl, pH 6.8 
3% dithiothreiltol 
4% SDS 
40% glycerol
0.005% bromophenol blue
Transfer buffer: 2.9g glycine
5.8g Tris-HCl 
0.37g SDS
200ml methanol, pH 8.3 per litre
Coomasie blue : 0.1%  Coomasie blue in water:methanol:acetic acid (5:5:2 by volume)
Tris-buffered saline (TBS): 6.05g Tris base
8.76g sodium chloride
800 ml distilled, water, adjust pH to 7.5 with hydrochloric acid
Tris buffered saline tween (TBST): 0.1% Tween 20/TBS
1% blocking solution: 1% skimmed milk in phosphae buffered saline pH 7.4
Ponceau S solution: 2g Ponceau S
30g trichloroacetic acid 
30g sulfosalcylic acid 
Add water to 100 ml
2X SDS loading buffer:
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D: pBlueBac transfer plasmid map, Vialard et a l., (1990)
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Appendix B: IgM antibody titre to CCHF virus in relation to day after the onset of illness as 
detected by IgM capture ELISA using sucrose acetone extracted antigen, in serum samples
collected from CCHF virus infected patients from 1986 to 1999.
Specim en num ber D av o f  illness IgM  titre In terp reta tion
70/98 D5 0 neg
198/96 D 6 0 neg
198/98 D 6 6400 pos
50/95 D6 1600 pos
47/97 /10 D7 0 neg
214/96 D7 6400 pos
51/95 D7 1600 pos
344/98 D7 1600 pos
184/96 D7 6400 pos
123/95 D7 100 neg
95/95 D8 100 neg
279/98 D8 6400 pos
74/96 D8 400 pos
48/97 /10 D8 0 neg
181/96 D8 0 neg
182/96 D8 6400 pos
55/95 D8 6400 pos
77/96 D9 1600 pos
58/95 D9 6400 pos
365/95 D9 1600 pos
193/96 D9 6400 pos
190/96 D9 6400 pos
201/96 D9 6400 pos
183/96 D9 6400 pos
288/98 D 10 6400 pos
47/97/5 D 10 6400 pos
197/96 D 10 6400 pos
207/96 D 10 0 neg
191/96 D 10 6400 pos
47 /97 /4 D 10 6400 pos
199/96 D 10 6400 pos
200 /96 D 10 6400 pos
208 /96 D 10 6400 pos
280/98 D 10 6400 pos
209 /96 D 10 6400 pos
226 /96 DIO 6400 pos
78/96 DIO 6400 pos
59/95 DIO 6400 pos
363/95 DIO 6400 pos
103/95 DIO 6400 pos
47/97 /12 D l l 6400 pos
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Appendix B (contd)
Specim en num ber D ay o f  illness IgM  titre In terpetation
104/95 D l l 6400 pos
81/96 D l l 400 pos
47/92/1 D l l 400 pos
62/95 D l l 6400 pos
47 /97 /2 D l l 6400 pos
192/96 D l l 6400 pos
47 /97 /9 D l l 400 pos
48/97/5 D l l 6400 pos
46/97/13 D l l 6400 pos
196/96 D l l 6400 pos
47/97/11 D l l 6400 pos
48 /97 /4 D l l 6400 pos
47/97 /14 D l l 6400 pos
47/97 /15 D l l 6400 pos
47/97 /12 D 12 6400 pos
81/98 D 12 1600 pos
194/96 D 12 1600 pos
47 /97 /2 D 12 6400 pos
48/97/3 D 12 6400 pos
48/97 /15 D 12 6400 pos
48 /97 /9 D 12 6400 pos
210/96 D 12 6400 pos
47/97/8 D 12 6400 pos
49 /97 /2 D 12 6400 pos
48/97/11 D 12 6400 pos
82/96 D 12 400 pos
63/95 D 12 6400 pos
370/95 D 12 6400 pos
105/95 D 12 6400 pos
48/97/1 D 12 1600 pos
48/97 /12 D 12 6400 pos
48 /97 /2 D 12 6400 pos
83/96 D13 100 neg
371/95 D13 6400 pos
48/97 /15 D13 6400 pos
47 /97 /6 D13 1600 pos
225 /96 D13 1600 pos
48/97/8 D13 6400 pos
48/97/13 D13 6400 pos
47/97 /16 D13 6400 pos
48/97 /16 D 14 6400 pos
372/95 D 14 6400 pos
48 /97 /6 D 14 1600 pos
84/96 D 14 400 pos
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Appendix B (contd)
S pecim en num ber D ay o f  illness IsM  titre In terp re ta tion
373/95 D 15 6400 pos
85/96 D 15 1600 pos
49/97/1 D 16 1600 pos
86/96 D 16 1600 pos
19/96 D 16 6400 pos
90/96 D 17 6400 pos
92/96 D 19 6400 pos
74/95 D 19 6400 pos
97/96 D21 6400 pos
374/95 D21 6400 pos
99/96 D 23 6400 pos
50/97/5 W K 4 6400 pos
50/97/4 W K 4 1600 pos
94/95 W K 4 6400 pos
50/97/2 W K 4 1600 pos
50/97/1 W K 4 6400 pos
50/97/6 W K 4 6400 pos
51/97/6 W K 5 0 neg
51/97/7 W K 5 0 neg
51/97/9 W K 5 1600 pos
51/97/1 W K 5 1600 pos
51/97/5 W K 5 0 neg
51/97/4 W K 5 1600 pos
51/97 /10 W K 5 6400 pos
51/97/8 W K 5 0 neg
51/97/1 W K 5 1600 pos
51/97/2 W K 5 1600 pos
51/97/11 W K5 400 pos
51/97/12 W K5 100 pos
40/99 W K 6 6400 pos
121/99 W K 14 6400 pos
43 /89 W K 17 0 neg
525/99 W K 17 6400 pos
309/87 W K 19 0 neg
219/89 W K 19 6400 pos
62/89 W K 19 0 neg
573/99 W K 20 6400 pos
131/87 W K21 0 neg
281/88 W K 26 6400 pos
140/96 W K 28 0 neg
350/89 W K 32 0 neg
298 /88 W K 33 0 neg
507/87 W K 33 0 neg
496 /87 W K 33 0 neg
247/88 W K 38 6400 pos
414/88 W K 40 6400 pos
73/89 W K 44 0 neg
413 /88 W K 45 6400 pos
508/87 M 13 0 neg
85/88 M 16 0 neg
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Appendix C: IgM antibody titre to CCHF virus in relation to day after the onset of illness as detected
by IgM capture ELISA using recombinant antigen, in serum samples collected from CCHF virus
infected patients from 1986 to 1999.
Specim en num ber D ay o f  illness IgM  titre In terp re ta tion
70/98 D5 0 neg
198/96 D6 0 neg
198/98 D 6 1600 pos
50/95 D6 1600 pos
47/97 /10 D7 0 neg
214/96 D7 6400 pos
51/95 D7 1600 pos
344/98 D7 400 pos
184/96 D7 6400 pos
123/95 D7 0 neg
95/95 D8 100 neg
279/98 D8 1600 pos
74/96 D8 0 neg
48 /97 /10 D8 0 neg
181/96 D8 0 neg
182/96 D8 1600 pos
55/95 D8 1600 pos
77/96 D9 0 neg
58/95 D9 6400 pos
365/95 D9 1600 pos
193/96 D9 6400 pos
190/96 D9 6400 pos
201 /96 D9 6400 pos
183/96 D9 1600 pos
288/98 D 10 6400 pos
47/97/5 D 10 6400 pos
197/96 D 10 1600 pos
207/96 D 10 0 neg
191/96 D 10 6400 pos
47 /97 /4 D 10 1600 pos
199/96 D 10 6400 pos
200 /96 D 10 6400 pos
208 /96 D 10 6400 pos
280/98 D 10 6400 pos
209 /96 D 10 6400 pos
226/96 D 10 1600 pos
78/96 D 10 100 neg
59/95 D 10 6400 pos
363/95 D 10 1600 pos
103/95 D 10 1600 pos
47/97 /12 D l l 6400 pos
104/95 D l l 1600 pos
81/96 D l l 400 pos
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Appendix C (contd)
Specim en nu m b er D ay o f  illness IgM  titre In terp re ta tion
47/92/1 D l l 100 neg
62/95 D l l 1600 pos
47 /97 /2 D l l 6400 pos
192/96 D l l 6400 pos
47 /97 /9 D l l 6400 pos
48/97/5 D l l 6400 pos
46/97 /13 D l l 1600 pos
196/96 D l l 6400 pos
47/97/11 D l l 6400 pos
48 /97 /4 D l l 1600 pos
47/97 /14 D l l 1600 pos
47/97 /15 D l l 1600 pos
47/97 /12 D 12 1600 pos
81/98 D 12 6400 pos
194/96 D 12 1600 pos
47 /97 /2 D 12 6400 pos
48/97/3 D 12 6400 pos
48/97 /15 D 12 6400 pos
48 /97 /9 D 12 1600 pos
210 /96 D 12 6400 pos
47 /97 /8 D 12 6400 pos
49 /97 /2 D 12 1600 pos
48/97/11 D 12 6400 pos
82/96 D 12 400 pos
63/95 D 12 6400 pos
370/95 D 12 6400 pos
105/95 D 12 1600 pos
48/97/1 D 12 1600 pos
48/97 /12 D 12 6400 pos
48 /97 /2 D 12 6400 pos
83/96 D13 100 neg
371/95 D13 6400 pos
48/97 /15 D13 1600 pos
47 /97 /6 D13 1600 pos
225 /96 D13 1600 pos
48 /97 /8 D13 1600 pos
48/97/13 D13 1600 pos
47/97 /16 D13 6400 pos
48/97 /16 D 14 6400 pos
372/95 D 14 6400 pos
48 /97 /6 D 14 1600 pos
84/96 D 14 400 pos
373/95 D15 6400 pos
85/96 D 15 1600 pos
49/97/1 D 16 1600 pos
86/96 D 16 400 pos
19/96 D 16 6400 pos
90/96 D 17 1600 pos
92/96 D 19 1600 pos
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Appendix C  (contd)
S D e c im e n  n u m b e r D ay o f  illness I a M  t i t r e I n t e r p r e t a t i o n
74/95 D 19 6400 pos
97/96 D21 1600 pos
374/95 D21 6400 pos
99/96 D23 1600 pos
50/97/4 W K 4 1600 pos
50/97/5 W K 4 1600 pos
94/95 W K 4 6400 pos
50/97/2 W K 4 0 n e g
50/97/1 W K 4 1600 pos
50/97/6 W K 4 1600 pos
51/97/6 W K5 0 n e g
51/97/7 W K5 0 n e g
51/97/9 W K 5 1600 pos
51/97/1 W K5 400 pos
51/97/5 W K 5 0 n e g
51/97/4 W K 5 0 n e g
51/97/10 W K 5 1600 pos
51/97/8 W K 5 0 n e g
51/97/1 W K 5 6400 pos
51/97/2 W K 5 1600 pos
51/97/11 W K5 400 pos
51/97 /12 W K5 400 pos
40/99 W K 6 6400 pos
121/99 W K 14 1600 pos
43/89 W K 17 0 n e g
525/99 W K 17 1600 pos
309/87 W K 19 0 n e g
219/89 W K 19 6400 pos
62/89 W K 19 0 n e g
573/99 W K 20 1600 pos
131/87 W K21 0 n e g
281/88 W K 26 1600 pos
140/96 W K 28 0 n e g
350/89 W K 32 0 n e g
298/88 W K 33 0 n e g
507/87 W K 33 0 n e g
496 /87 W K 33 0 n e g
247/88 W K 38 1600 pos
414/88 W K 40 400 pos
73/89 W K 44 0 n e g
413/88 W K 45 400 pos
508/87 M 13 0 n e g
85/88 M 16 0 n e g
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Appendix D: IgG antibody titre to CCHF virus in relation to day after the onset of illness as detected
by IgG sandwich ELISA using sucrose acetone extracted antigen, in serum samples collected from
CCHF virus infected patients from 1986 to 1999.
S pecim en n um ber D ay o f  illness IgG  titre In terp reta tion
70/98 D5 0 neg
198/96 D6 0 neg
50/95 D6 0 neg
198/98 D6 0 neg
214/96 D7 1600 pos
123/95 D7 0 neg
47/97 /10 D7 0 neg
51/95 D7 0 neg
184/96 D7 400 pos
344/98 D7 400 pos
55/95 D8 400 pos
95/95 D8 0 neg
182/96 D8 400 pos
48/97 /10 D8 0 neg
279/98 D8 0 neg
74/96 D8 0 neg
181/96 D8 0 neg
58/95 D9 1600 pos
201 /96 D9 400 pos
183/96 D 9 400 pos
190/96 D9 1600 pos
193/96 D9 400 pos
77/96 D9 100 pos
365/95 D9 0 neg
197/96 D10 1600 pos
47 /97 /5 D 10 400 pos
288/98 D 10 400 pos
363/95 D 10 100 pos
47 /97 /4 D 10 1600 pos
191/96 D 10 1600 pos
78/96 D 10 100 pos
207/96 D 10 0 neg
199/96 D 10 6400 pos
226 /96 D 10 400 pos
208 /96 D 10 6400 pos
200 /96 D 10 1600 pos
103/95 D 10 100 pos
280/98 D 10 400 pos
209 /96 D 10 6400 pos
59/95 D 10 1600 pos
47 /97 /14 D l l 1600 pos
47/97 /15 D l l 1600 pos
46/97 /13 D l l 100 pos
81/96 D l l 400 pos
104/95 D l l 6400 pos
85
Appendix D(contd)
Specim en num ber D av o f  illness laG  titre In terp reta tion
62/95 D l l 6400 pos
192/96 D l l 6400 pos
47 /97 /2 D l l 1600 pos
47/92/1 D l l 1600 pos
47 /97 /9 D l l 400 pos
47/97/11 D l l 6400 pos
47/97 /12 D l l 400 pos
48 /97 /4 D l l 1600 pos
48/97/5 D l l 1600 pos
196/96 D l l 1600 pos
48/97/1 D 12 400 pos
48/97/11 D 12 6400 pos
49 /97 /2 D 12 400 pos
47 /97 /2 D 12 6400 pos
48/97 /15 D 12 1600 pos
210/96 D 12 400 pos
48 /97 /12 D 12 100 pos
47/97 /12 D 12 400 pos
48 /97 /9 D 12 400 pos
105/95 D 12 6400 pos
63/95 D 12 6400 pos
82/96 D 12 1600 pos
370/95 D 12 6400 pos
48 /97 /2 D 12 6400 pos
47 /97 /8 D 12 1600 pos
48/97/3 D 12 6400 pos
194/96 D 12 400 pos
81/98 D 12 100 pos
371/95 D13 6400 pos
48/97/13 D13 400 pos
83/96 D13 1600 pos
225 /96 D13 1600 pos
47 /97 /6 D13 100 pos
48 /97 /8 D13 1600 pos
48/97 /15 D 13 1600 pos
47/97 /16 D13 400 pos
48 /97 /6 D 14 400 pos
48/97 /16 D 14 400 pos
372/95 D 14 6400 pos
84/96 D 14 1600 pos
373/95 D15 6400 pos
85/96 D15 6400 pos
86/96 D 16 6400 pos
19/96 D 16 6400 pos
49/97/1 D 16 1600 pos
90/96 D 17 6400 pos
92/96 D19 6400 pos
74/95 D 19 6400 pos
97/96 D21 6400 pos
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Appendix D(contd)
Specim en num ber D ay o f  illness IgG  titre In terp reta tion
374/95 D21 6400 pos
99/96 D23 6400 pos
50/97/6 W K 4 6400 pos
50/97/5 W K 4 6400 pos
50/97/2 W K 4 6400 pos
50/97/1 W K 4 6400 pos
94/95 W K 4 6400 pos
50/97/4 W K 4 6400 pos
51/97/7 W K5 6400 pos
51/97/6 W K 5 6400 pos
51/97/1 W K 5 6400 pos
51/97/5 W K5 6400 pos
51/97/4 W K5 6400 pos
51/97/2 W K5 6400 pos
51/97/8 W K5 6400 pos
51/97/1 W K5 6400 pos
51/97/12 W K5 6400 pos
51/97/10 W K5 6400 pos
51/97/9 W K5 6400 pos
51/97/11 W K5 6400 pos
40/99 W K 6 6400 pos
121/99 W K 14 6400 pos
525/99 W K 17 6400 pos
43/89 W K 17 6400 pos
309/87 W K 19 6400 pos
219 /89 W K 19 6400 pos
62/89 W K 19 6400 pos
573/99 W K 20 6400 pos
131/87 W K21 6400 pos
281/88 W K 26 6400 pos
140/96 W K 28 6400 pos
350/89 W K 32 0 neg
507/87 W K 33 6400 pos
496 /87 W K 33 6400 pos
298/88 W K 33 6400 pos
247/88 W K 38 6400 pos
414/88 W K 40 6400 pos
73/89 W K 44 6400 pos
413/88 W K 45 6400 pos
508/87 M 13 6400 pos
85/88 M 16 6400 pos
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Appendix E: IgG antibody titre to CCHF virus in relation to day after the onset of illness as detected
by IgG sandwich ELISA using recombinant antigen, in serum samples collected from CCHF virus
infected patients from 1986 to 1999.
S pecim en num ber D ay o f  illness IgG  titre In terpreta tion
70/98 D5 0 neg
198/96 D6 0 neg
198/98 D6 0 neg
50/95 D6 0 neg
184/96 D 7 400 pos
51/95 D7 0 neg
214/96 D7 100 pos
123/95 D7 0 neg
344/98 D7 400 pos
47/97 /10 D7 0 neg
55/95 D8 400 pos
182/96 D8 0 neg
279/98 D8 0 neg
48/97 /10 D8 0 neg
95/95 D8 0 neg
74/96 D8 0 neg
181/96 D8 0 neg
190/96 D9 0 neg
77/96 D9 100 pos
183/96 D9 400 pos
365/95 D9 0 neg
201 /96 D9 100 pos
193/96 D9 100 pos
58/95 D9 1600 pos
47/97/5 D 10 400 pos
197/96 D10 400 pos
288/98 D10 400 pos
207/96 D 10 0 neg
191/96 D 10 400 pos
47 /97 /4 D 10 400 pos
199/96 D 10 6400 pos
200 /96 D 10 100 pos
208 /96 D 10 1600 pos
280/98 D 10 100 pos
209/96 D 10 400 pos
226/96 D 10 400 pos
78/96 D 10 100 pos
59/95 D 10 100 pos
363/95 D 10 400 pos
103/95 D 10 100 pos
192/96 D l l 400 pos
47 /97 /2 D l l 1600 pos
81/96 D l l 400 pos
47/92/1 D l l 100 pos
62/95 D l l 100 pos
104/95 D l l 100 pos
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Appendix E(contd)
Specim en num ber D av o f  illness IaG  titre In terpreta tion
48 /97 /4 D l l 400 pos
47/97 /14 D l l 1600 pos
196/96 D l l 400 pos
47 /97 /9 D l l 400 pos
46/97/13 D l l 100 pos
47/97 /12 D l l 100 pos
48/97/5 D l l 400 pos
47/97 /15 D l l 1600 pos
47/97/11 D l l 6400 pos
82/96 D 12 100 pos
47 /97 /8 D 12 400 pos
194/96 D 12 400 pos
210 /96 D 12 400 pos
48/97/11 D 12 6400 pos
81/98 D 12 100 pos
49 /97 /2 D 12 100 pos
63/95 D 12 400 pos
48 /97 /9 D 12 400 pos
48/97 /12 D 12 400 pos
47/97 /12 D 12 100 pos
48 /97 /2 D 12 1600 pos
48/97 /15 D 12 1600 pos
370/95 D 12 100 pos
105/95 D 12 100 pos
47 /97 /2 D 12 1600 pos
48/97/3 D 12 1600 pos
48/97/1 D 12 100 pos
48/97/15 D13 1600 pos
83/96 D13 400 pos
225/96 D13 400 pos
371/95 D13 100 pos
47 /97 /6 D13 400 pos
48 /97 /8 D13 400 pos
48/97/13 D13 400 pos
47/97 /16 D13 400 pos
372/95 D 14 1600 pos
84/96 D 14 1600 pos
48 /97 /6 D 14 400 pos
48/97 /16 D 14 400 pos
373/95 D15 1600 pos
85/96 D15 1600 pos
86/96 D 16 400 pos
19/96 D 16 1600 pos
49/97/1 D 16 400 pos
90/96 D 17 6400 pos
92/96 D 19 6400 pos
74/95 D 19 1600 pos
97/96 D21 1600 pos
89
Appendix E(contd)
SDecimen num ber D av o f  illness IaG  titre In terpreta tion
374/95 D21 6400 pos
99/96 D23 6400 pos
50/97/5 W K 4 6400 pos
50/97/4 W K 4 1600 pos
94/95 W K 4 6400 pos
50/97/2 W K 4 1600 pos
50/97/6 W K 4 400 pos
50/97/1 W K 4 1600 pos
51/97/6 W K5 6400 pos
51/97/7 W K5 6400 pos
51/97/9 W K5 6400 pos
51/97/1 W K5 6400 pos
51/97/5 W K5 6400 pos
51/97/4 W K5 1600 pos
51/97/10 W K5 6400 pos
51/97/8 W K 5 6400 pos
51/97/1 W K 5 1600 pos
51/97/2 W K 5 6400 pos
51/97/11 W K 5 1600 pos
51/97/12 W K5 1600 pos
40 /99 W K 6 6400 pos
121/99 W K 14 6400 pos
43 /89 W K 17 6400 pos
525/99 W K 17 6400 pos
219/89 W K 19 6400 pos
309/87 W K 19 6400 pos
62/89 W K 19 6400 pos
573/99 W K 20 6400 pos
131/87 W K21 6400 pos
281/88 W K 26 6400 pos
140/96 W K 28 6400 pos
350/89 W K 32 0 neg
298/88 W K 33 6400 pos
507/87 W K 33 6400 pos
496/87 W K 33 6400 pos
247/88 W K 38 6400 pos
414/88 W K 40 6400 pos
73/89 W K 44 6400 pos
413/88 W K 45 6400 pos
508/87 M 13 6400 pos
85/88 M 16 6400 pos
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Appendix F: Total antibody titre to CCHF virus in relation to day after the onset of illness as detected
by CELISA using sucrose acetone extracted antigen, in serum samples from CCHF virus infected
patients collected from 1986 to 1999
S pecim en num ber D ay o f  illness T otal an tibody  titre In terp re ta tion
70/98 D5 0 neg
198/96 D 6 0 neg
198/98 D 6 0 neg
50/95 D 6 0 neg
47/97 /10 D 7 40 pos
214/96 D7 40 pos
51/95 D7 80 pos
344/98 D 7 0 neg
184/96 D 7 160 pos
123/95 D 7 0 neg
95/95 D8 80 pos
279/98 D8 20 pos
74/96 D8 0 neg
48/97 /10 D8 320 pos
181/96 D8 0 neg
182/96 D8 40 pos
55/95 D8 0 neg
77/96 D9 80 pos
58/95 D9 0 neg
365/95 D9 40 pos
193/96 D9 0 neg
190/96 D 9 40 pos
201 /96 D 9 40. pos
183/96 D 9 40 pos
288/98 D 10 80 pos
47/97/5 D 10 40 pos
197/96 D 10 20 pos
207/96 D 10 40 pos
191/96 D 10 0 neg
47 /97 /4 D 10 320 pos
199/96 D 10 0 neg
200/96 D 10 40 pos
208/96 D 10 320 pos
280/98 D 10 80 pos
209 /96 D 10 160 pos
226 /96 D 10 160 pos
78/96 D 10 160 pos
59/95 D 10 160 pos
363/95 D 10 40 pos
103/95 D 10 40 pos
47/97 /12 D l l 40 pos
104/95 D l l 20 pos
81/96 D l l 0 neg
47/92/1 D l l 0 neg
62/95 D l l 40 pos
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Appendix F(contd)
Specim en num ber D av o f  illness T otal an tibody  titre In terp re ta tion
47 /97 /2 D l l 40 pos
192/96 D l l 20 pos
47 /97 /9 D l l 0 neg
48 /97 /5 D l l 160 P0S
46/97/13 D l l 40 pos
196/96 D l l 160 pos
47/97/11 D l l 0 neg
48 /97 /4 D l l 0 neg
47/97 /14 D l l 20 pos
47/97 /15 D l l 20 pos
47/97 /12 D 12 40 pos
81/98 D 12 0 neg
194/96 D 12 40 pos
47 /97 /2 D 12 0 neg
48/97/3 D 12 0 neg
48/97 /15 D 12 40 pos
48 /97 /9 D 12 40 pos
210/96 D 12 40 pos
47/97/8 D 12 0 neg
49 /97 /2 D 12 160 pos
48/97/11 D 12 160 pos
82/96 D 12 40 pos
63/95 D 12 0 neg
370/95 D 12 20 pos
105/95 D 12 20 pos
48/97/1 D 12 40 pos
48/97 /12 D 12 20 pos
48/97/2 D 12 0 neg
83/96 D13 40 pos
371/95 D 13 0 neg
48/97/15 D13 40 pos
47 /97 /6 D13 40 pos
225 /96 D 13 80 pos
48 /97 /8 D 13 0 neg
48/97/13 D 13 0 neg
47/97 /16 D 13 80 pos
48/97 /16 D 14 80 pos
372/95 D 14 0 neg
48 /97 /6 D 14 40 pos
84/96 D 14 40 pos
373/95 D15 40 pos
85/96 D 15 40 pos
49/97/1 D 16 80 pos
86/96 D 16 40 pos
19/96 D 16 40 pos
90/96 D 17 80 pos
92/96 D 19 160 pos
74/95 D 19 80 pos
97/96 D21 80 pos
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Appendix F(contd)
S pecim en n um ber D av o f  illness T otal an tibody  titre In terp re ta tion
374/95 D21 80 pos
99/96 D23 80 pos
50/97/4 W K 4 80 pos
50/97/5 W K 4 40 pos
94/95 W K 4 40 pos
50/97/2 W K 4 40 pos
50/97/1 W K 4 0 neg
50/97/6 W K 4 20 pos
51/97/6 W K 5 80 pos
51/97/7 W K 5 80 pos
51/97/9 W K 5 40 pos
51/97/1 W K 5 40 pos
51/97/5 W K 5 40 pos
51/97/4 W K 5 40 pos
51/97 /10 W K 5 40 pos
51/97/8 W K 5 40 pos
51/97/1 W K 5 20 pos
51/97/2 W K 5 80 pos
51/97/11 W K 5 40 pos
51/97/12 W K 5 40 pos
40/99 W K 6 320 pos
121/99 W K 14 640 pos
43/89 W K 17 2560 pos
525/99 W K 17 2560 pos
309/87 W K 19 320 pos
219/89 W K 19 640 pos
62/89 W K 19 320 pos
573/99 W K 20 160 pos
131/87 WK.21 2560 pos
281/88 W K 26 1280 pos
140/96 W K 28 320 pos
350/89 WK.32 0 neg
298/88 WK.33 320 pos
507/87 W K 33 80 pos
496 /87 WK.33 320 pos
247/88 W K 38 1280 pos
414 /88 W K 40 1280 pos
73/89 W K 44 40 pos
413 /88 W K 45 640 pos
508/87 M 13 640 pos
85/88 M 16 1280 pos
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Appendix G: Total antibody titre to CCHF virus in relation to day after the onset of illness detected
by CELISA using recombinant antigen, in serum samples from CCHF virus infected patients collected
from 1986 to 1999.
Specim en num ber D ay o f  illness T otal an tibody  titre In terp re ta tion
70/98 D5 0 neg
198/96 D 6 40 pos
198/98 D 6 0 neg
50/95 D 6 0 neg
47/97 /10 D7 80 pos
214/96 D7 40 pos
51/95 D7 40 pos
344/98 D7 0 neg
184/96 D7 80 pos
123/95 D7 0 neg
95/95 D8 160 pos
279/98 D8 80 pos
74/96 D8 0 neg
48 /97 /10 D8 0 neg
181/96 D8 80 pos
182/96 D8 0 neg
55/95 D8 20 pos
77/96 D9 160 pos
58/95 D9 160 pos
365/95 D9 0 neg
193/96 D9 40 pos
190/96 D9 40 pos
201 /96 D9 40 pos
183/96 D9 20 pos
288/98 D 10 160 pos
47/97/5 D 10 160 pos
197/96 D 10 160 pos
207 /96 D 10 160 pos
191/96 D 10 0 neg
47 /97 /4 D 10 160 pos
199/96 D 10 0 neg
200 /96 D 10 40 pos
208 /96 D 10 80 pos
280/98 D 10 320 pos
209 /96 D 10 160 pos
226 /96 D 10 40 pos
78/96 D 10 80 pos
59/95 D 10 80 pos
363/95 D 10 80 pos
103/95 D 10 40 pos
47/97 /12 D l l 160 pos
104/95 D l l 80 pos
81/96 D l l 20 pos
47/92/1 D l l 0 neg
62/95 D l l 80 pos
47 /97 /2 D l l 80 pos
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Appendix G(contd)
Specim en nu m b er D ay o f  illness T otal an tibody  titre In terp reta tion
192/96 D l l 80 pos
47 /97 /9 D l l 40 pos
48/97/5 D l l 80 pos
46/97/13 D l l 40 pos
196/96 D l l 40 pos
47/97/11 D l l 40 pos
48 /97 /4 D l l 0 neg
47/97 /14 D l l 40 pos
47/97 /15 D l l 40 pos
47/97 /12 D 12 80 pos
81/98 D 12 40 pos
194/96 D 12 80 pos
47 /97 /2 D 12 0 neg
48/97/3 D 12 40 pos
48/97 /15 D 12 80 pos
48 /97 /9 D 12 80 pos
210 /96 D 12 80 pos
47/97/8 D 12 160 pos
49 /97 /2 D 12 40 pos
48/97/11 D 12 80 pos
82/96 D 12 40 pos
63/95 D 12 40 pos
370/95 D 12 40 pos
105/95 D 12 40 pos
48/97/1 D 12 80 pos
48/97 /12 D 12 0 neg
48 /97 /2 D 12 20 pos
83/96 D13 640 pos
371/95 D13 0 neg
48/97 /15 D13 40 pos
47 /97 /6 D13 0 neg
225 /96 D13 40 pos
48 /97 /8 D13 0 neg
48/97/13 D13 40 pos
47/97 /16 D13 80 pos
48 /97 /16 D 14 80 pos
372/95 D 14 0 neg
48 /97 /6 D 14 0 neg
84/96 D 14 40 pos
373/95 D15 80 pos
85/96 D15 80 pos
49/97/1 D 16 320 pos
86/96 D 16 40 pos
19/96 D 16 40 pos
90/96 D 17 80 pos
92/96 D 19 160 pos
74/95 D 19 160 pos
97/96 D21 320 pos
374/95 D21 40 pos
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Appendix G(contd)
Specim en num ber D ay o f  illness T otal an tibody  titre In terp reta tion
99/96 D23 80 pos
50/97/4 W K 4 320 pos
50/97/5 W K 4 0 neg
94/95 W K 4 20 pos
50/97/2 W K 4 40 pos
50/97/1 W K 4 0 neg
50/97/6 W K 4 40 pos
51/97/6 W K 5 40 pos
51/97/7 W K 5 40 pos
51/97/9 W K 5 80 pos
51/97/1 W K 5 80 pos
51/97/5 W K 5 40 pos
51/97/4 W K 5 0 neg
51/97 /10 W K 5 40 pos
51/97/8 W K 5 40 pos
51/97/1 W K 5 40 pos
51/97/2 W K 5 80 pos
51/97/11 W K 5 80 pos
51/97 /12 W K 5 20 pos
40/99 W K 6 320 pos
121/99 W K 14 1280 pos
43/89 W K 17 1280 pos
525/99 W K 17 640 pos
309/87 W K 19 640 pos
219 /89 W K 19 80 pos
62/89 W K 19 640 pos
573/99 W K 20 1280 pos
131/87 W K21 2560 pos
281/88 W K 26 1280 pos
140/96 W K 28 640 pos
350/89 W K 32 0 neg
298/88 W K 33 320 pos
507/87 W K 33 1280 pos
496 /87 W K 33 80 pos
247/88 W K 38 1280 pos
414/88 W K 40 1280 pos
73/89 W K 44 40 pos
413/88 W K 45 1280 pos
508/87 M 13 1280 pos
85/88 M 16 1280 pos
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AppendixH: Optical density (OD) values obtained from screening non-CCHF patients by ELISA. 
Serum samples were tested by ELISA for detection of IgG, IgM and total antibody using sucrose 
acetone extracted (sa) and recombinant antigen (rec).
S P U  n o . IqG  s a 1 IqG  rec2 laM  s a 1 IqM  rec2 C E L IS A  s a 1 C E LIS A  re d
147/00 0.185 0.155 0.123 0.141 1.228 1.279
150/00 0.239 0.193 0.141 0 .159 1.178 1.399
152/00 0.211 0.174 0.224 0 .222 1.082 1.136
153/00 0.166 0.152 0.122 0 .129 1.153 1.171
155/00 0.205 0.188 0.132 0.161 1.075 0.835
156/00 0.251 0.207 0.131 0 .152 1.148 1.213
157/00 0.146 0.154 0.126 0.13 1.039 1.165
159/00 0.187 0.17 0.127 0 .147 0.991 1.22
160/00 0.128 0.117 0.138 0.152 1.09 1.226
165/00 0.201 0.144 0 .126 0 .134 0 .987 1.118
166/00 0.176 0.15 0.143 0.158 1.006 1.23
168/00 0.247 0.172 0 .167 0 .196 1.074 1.032
178/00 0.381 0.232 0 .127 0.141 1.057 1.164
180.1/00 0.192 0.159 0.242 0.243 1.054 1.237
180.2/00 0.36 0.265 0.18 0.212 1.033 1.309
180.3/00 0.199 0.18 0 .116 0.143 1.056 1.231
180.4/00 0 .167 0.081 0.155 0.182 0 .999 0.854
180.5/00 0.185 0.161 0.134 0.155 1.126 1.065
180.6/00 0.22 0.206 0 .139 0.148 1.094 1.219
180.7/00 0.153 0.136 0.121 0 .139 1.165 1.264
180.8/00 0.172 0.142 0.131 0 .149 1.148 1.173
182/00 0.155 0.143 0.117 0.131 1.058 1.148
183/00 0.363 0.311 0.132 0.147 0.949 1.115
184/00 0 .219 0.175 0.123 0.137 1.057 1.221
186/00 0 .297 0.239 0.11 0.119 1.086 1.128
188/00 0.225 0.201 0.116 0.128 1.031 1.138
189/00 0 .269 0.199 0 .159 0.181 0.993 1.202
191/00 0.2 0.164 0 .219 0 .258 1.026 1.156
193/00 0.228 0.172 0.121 0 .134 1.102 0.936
196/00 0.093 0.091 0.209 0 .257 1.152 1.188
197/00 0.23 0.247 0.194 0.235 1.196 1.227
201 /00 0.193 0.156 0.125 0.141 1.016 1.099
202 /00 0.255 0.214 0.104 0 .114 0 .869 1.026
205 /00 0.15 0.129 0.103 0 .117 0.813 1.177
206 /00 0.165 0.147 0.106 0 .12 0 .859 0.997
207 /00 0.195 0.231 0.114 0 .127 0.972 1.138
210 /00 0.203 0.168 0.119 0.123 1.101 1.129
211 /00 0.16 0.163 0 .117 0.122 1.193 1.057
212 /00 0.362 0.287 0 .139 0 .137 1.019 1.179
214 /00 0.236 0.182 0.111 0.108 1.026 1.152
215 /00 0.237 0.194 0.112 0 .108 0.997 1.003
216 /00 0.091 0.192 0.155 0 .14 1.002 0.939
217 /00 0.095 0.179 0.228 0.217 1.237 1.051
219 /00 0 .236 0.167 0.116 0.107 1.145 1.041
223 /00 0.291 0.24 0.129 0.115 1.257 0.972
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A p p e n d ix  
SPU  n o .
H  ( c o n td )  
IqG s a laG  rec laM s a IqM rec C EL ISA  s a C ELISA  rec
225 /00 0.188 0.178 0.132 0.122 1.097 1.005
228 /00 0.105 0.193 0.117 0.111 1.143 1.005
231 /00 0 .299 0.248 0.143 0 .134 1.174 1.11
233 /00 0.39 0.318 0.124 0 .12 1.061 1.17
234 /00 0.286 0.189 0.115 0.113 1.035 1.162
237 /00 0.2 0.18 0.115 0.111 1.041 1.149
238 /00 0.381 0.328 0.118 0 .186 0.987 1.051
239 /00 0.087 0.227 0.102 0.102 0.988 0.989
240 /00 0.352 0.291 0.118 0 .116 1 1.069
242 /00 0.361 0.299 0.228 0.208 1.005 0.948
248/00 0.294 0.207 0.181 0.198 1.3 0.995
249/00 0.12 0.111 0.113 0.122 1.149 1.018
250/00 0.265 0.194 0.121 0.125 1.113 1.073
251 /00 0.102 0.092 0.17 0.168 1.005 1.174
256 /00 0.21 0.188 0.128 0.132 1.215 1.206
259 /00 0 .176 0.151 0.114 0.117 1.107 1.206
263 /00 0.225 0.197 0.117 0 .119 0.903 1.23
269 /00 0.212 0 .16 0.121 0 .12 1.021 1.085
270 /00 0.207 0.151 0.106 0.126 1.057 1.118
271 /00 0.247 0.192 0.127 0.126 1.186 1.065
273 /00 0 .219 0.2 0.115 0.118 1.118 1.063
277 /00 0 .209 0 .187 0.139 0 .144 1.111 1.0011
279 /00 0 .259 0 .232 0.115 0 .122 1.197 1.082
280 /00 0 .106 0 .092 0.188 0 .194 1.08 1.533
282 /00 0.221 0.201 0.13 0 .134 1.095 1.246
283 /00 0.224 0 .207 0.123 0.125 1.195 1.287
284 /00 0.164 0 .138 0.132 0.135 1.056 1.169
285 /00 0.2 0 .159 0 .154 0 .154 1.128 1.196
287 /00 0.193 0.163 0.123 0 .122 1.065 1.182
288 /00 0.217 0 .186 0.128 0.133 1.119 1.172
289/00 0.31 0.308 0 .124 0.125 1.044 1.071
290/00 0.271 0 .224 0 .119 0 .116 1.314 1.108
296/00 0.216 0 .196 0 .116 0 .116 1.083 1.145
297/00 0.252 2 .116 0 .154 0 .144 1.106 1.097
300 /00 0.221 0.185 0 .136 0.122 1.151 1.158
303 /00 0.129 0.163 0 .154 0 .16 1.102 1.205
15/01 0.255 0 .256 0 .136 0.142 1.323 1.153
18/01 0.176 0 .179 0 .146 0 .156 1.04 1.157
26/01 0.204 0.183 0.133 0 .144 1.194 1.21
27/01 0.322 0 .296 0.183 0 .196 1.141 1.262
29/01 0.281 0.313 0 .156 0 .16 1.09 1.173
31/01 0.343 0.225 0.168 0 .174 1.02 1.1
33/01 0.105 0 .228 0.162 0 .174 1.041 1.26
35/01 0.098 0.091 0.174 0 .177 1.131 1.17
39/01 0.213 0.201 0.13 0.137 1.163 1.154
40/01 0.249 0.231 0 .114 0.122 1.123 1.121
45/01 0.351 0.283 0.125 0.131 1.336 1.124
48/01 0.105 0.19 0.143 0.143 1.132 1.249
55/01 0.248 0.227 0 .134 0 .14 1.153 1.098
58/01 0.095 0.088 0.195 0 .159 1.174 1.204
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A p p e n d ix  
S P U  n o .
H  ( c o n td ) 
laG  sa IqG  rec laM  sa
59/01 0.338 0 .256 0.132
60/01 0.301 0.265 0.261
61/01 0.304 0.285 0.12
62/01 0.095 0 .286 0.145
71/01 0.113 0 .109 0.136
73/01 0.22 0.193 0.165
75/01 0.268 0.257 0.136
78/01 0 .196 0.161 0.121
79/01 0 .239 0.225 0.183
80/01 0.228 0 .196 0.136
82/01 0.36 0.312 0.171
84/01 0.296 0.167 0.126
86/01 0.241 0.082 0.131
88/01 0 .316 0.221 0.134
96/01 0 .196 0.155 0.164
101/01 0 .299 0.231 0.126
107/01 0 .297 0.241 0.149
110/01 0 .246 0.222 0.118
117/01 0.25 0.197 0.134
121/01 0.133 0.085 0.12
123/01 0 .369 0.297 0.312
129/01 0.187 0 .17 0.125
130/01 0.169 0 .158 0.111
132/01 0.259 0 .239 0.117
133/01 0.299 0 .314 0.151
134/01 0.202 0.185 0.147
135/01 0.246 0 .219 0.133
136/01 0.157 0 .164 0.128
142/01 0.133 0 .129 0.115
144/01 0.299 0 .284 0.112
157/01 0.277 0 .249 0.147
158/01 0.28 0 .24 0.117
160/01 0 .266 0 .236 0.13
162/01 0 .209 0.181 0.111
166/01 0.169 0 .169 0.105
167/01 0.204 0.195 0.106
169/01 0.204 0 .16 0.099
172/01 0.146 0 .167 0.093
177/01 0.142 0.133 0.106
181/01 0.127 0 .122 0.105
182/01 0.126 0 .124 0.111
184/01 0.126 0 .137 0.108
185/01 0.382 0 .368 0.196
186/01 0 .276 0 .212 0.103
187/01 0.152 0 .144 0.119
188/01 0.177 0 .154 0.18
193/01 0.182 0 .146 0.098
197/01 0.184 0 .166 0.142
200/01 0.23 0.205 0.123
201/01 0.1 0.116 0.121
laM  rec C E L IS A  sa C E L IS A  rec
0.153 1.09 1.234
0.262 1.105 1.26
0.123 1.158 1.238
0.185 0 .96 1.219
0.136 1.033 1.127
0.174 1.079 1.003
0.147 1.193 1.088
0.132 1.053 1.109
0.19 1.006 1.094
0.15 1.172 1.158
0.177 1.121 1.128
0.128 1.028 1.191
0.134 1.077 1.215
0.143 1.004 1.153
0.176 1.162 1.141
0.131 1.222 1.127
0.144 1.194 1.045
0.12 0 .992 1.101
0.14 1.323 1.268
0.123 1.078 1.205
0.336 0.95 1.12
0.131 0 .952 0 .752
0.111 0 .924 1.094
0.117 0.875 1.091
0.116 0.928 1.143
0.159 0.885 1.102
0 .14 1.032 1.252
0.141 0.985 1.135
0.163 1.046 0 .988
0.13 0.982 1.072
0.159 1.102 0.955
0.123 0.973 0 .768
0 .14 0.915 1.059
0.117 0 .916 1.055
0.107 0 .959 1.045
0.108 0 .956 1.033
0.103 0 .87 1.004
0.097 0.923 0.949
0.117 0.904 0.966
0.115 0.928 0.949
0.129 0.991 1.043
0.124 1.073 1.014
0.222 1.074 1.115
0.112 0 .952 0.973
0.129 0 .937 1.181
0.207 0.833 1.174
0.105 0 .912 0.953
0.157 0.823 0 .994
0.138 0 .869 1.02
0 .14 1.03 0.981
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A p p e n d ix  
S P U  n o .
H ( c o n td ) 
IqG  sa IqG  rec IqM  sa IqM  rec C E L IS A  sa C E L IS A  rec
202/01 0.266 0 .217 0.124 0.146 1.05 0.961
203/01 0.22 0.193 0.108 0.124 0 .989 0.993
204/01 0.195 0.177 0.106 0.13 1.122 1.156
205/01 0.268 0.216 0.118 0.13 1.038 1.192
210/01 0.13 0.111 0 .0109 0.115 1.038 0.953
212/01 0.172 0.145 0 .107 0 .117 1.125 1.282
215/01 0.078 0.077 0 .159 0.174 0.963 1.184
218/01 0.239 0.178 0.116 0 .126 1.004 1.13
221/01 0.199 0.17 0 .107 0.115 0.909 1.103
223/01 0.155 0.118 0.105 0.111 1.003 1.096
228/01 0 .264 0.25 0.111 0.124 1.004 1.059
231/01 0.21 0.281 0.157 0.193 1.069 1.112
233/01 0.083 0.091 0.195 0 .207 1.185 1.183
239/01 0.165 0.143 0.133 0.155 1.144 1.246
242/01 0 .164 0.136 0.135 0 .149 0 .96 0.812
s a ' : s u c ro s e  a c e to n e  e x t r a c te d  a n t ig e n
r e c 2: r e c o m b in a n t  a n t ig e n .
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Appendix I: IgM antibody titre to CCHF virus in relation to day post infection as detected by IgM
capture ELISA using sucrose acetone extracted antigen and recombinant antigen in serum samples
collected from an experimentally infected sheep (number 92).
sucrose acetone antigen Recombinant antigen
Day IeM titre Interpretation IeM titre Interpretation
0 0 neg 0 neg
1 0 neg 0 neg
2 0 neg 0 neg
3 0 neg 0 neg
4 0 neg 0 neg
5 0 neg 0 neg
6 0 neg 0 neg
7 1600 pos 1600 pos
8 1600 pos 1600 pos
9 6400 pos 6400 pos
10 6400 pos 1600 pos
11 6400 pos 1600 pos
12 6400 pos 6400 pos
13 6400 pos 1600 pos
14 1600 pos 6400 pos
21 400 pos 100 neg
28
Months
100 neg 100 neg
5 0 neg 0 neg
6 0 neg 0 neg
7 0 neg 0 neg
8 0 neg 0 neg
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Appendix J: IgM antibody titre to CCHF virus in relation to day post infection as detected by IgM
capture ELISA using sucrose acetone extracted and recombinant antigen in serum sample collected
from an sheep (number 48).
sucrose acetone antigen Recombinant antigen
Day IaM titre Interpretation IgM titre Interpretation
0 0 neg 0 neg
1 0 neg 0 neg
2 0 neg 0 neg
3 0 neg 0 neg
4 0 neg 0 neg
5 0 neg 0 neg
6 0 neg 0 neg
7 400 pos 100 neg
8 1600 pos 1600 pos
9 1600 pos 400 pos
10 1600 pos 400 pos
11 1600 pos 400 pos
12 1600 pos 400 pos
13 1600 pos 400 pos
14 400 pos 100 neg
21 400 pos 100 neg
28 0 neg 0 neg
Months
5 0 neg 0 neg
6 0 neg 0 neg
7 0 neg 0 neg
8 0 neg 0 neg
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Appendix K: IgM antibody titre to CCHF virus in relation to day post infection as detected by IgM
capture ELISA using sucrose acetone extracted and recombinant antigen in serum samples collected
from an experimentally infected sheep (number 37).
sucrose acetone antigen Recombinant antigen
Day IaM titre Interpretation I2M titre Interoretatio
0 0 neg 0
n
neg
1 0 neg 0 neg
2 0 neg 0 neg
3 0 neg 0 neg
4 100 neg 100 neg
5 400 pos 100 neg
6 1600 pos 400 pos
7 1600 pos 400 pos
8 1600 pos 400 pos
9 1600 pos 400 pos
10 1600 pos 6400 pos
11 6400 pos 1600 pos
12 1600 pos 400 pos
13 1600 pos 400 pos
14 400 pos 400 pos
21 0 neg 0 neg
28
Months
0 neg 0 neg
5 0 neg 0 neg
6 0 neg 0 neg
7 0 neg 0 neg
8 0 neg 0 neg
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Appendix L: IgG antibody titre to CCHF virus in relation to day post infection as detected by IgG
sandwich ELISA using sucrose acetone extracted and recombinant antigen in serum samples collected
from an experimentally infected sheep (number 92).
sucrose acetone antigen Recombinant antigen
Day IgG titre Interpretation IgG titre Interpretation
0 0 neg 0 neg
1 0 neg 0 neg
2 0 neg 0 neg
3 0 neg 0 neg
4 0 neg 0 neg
5 0 neg 0 neg
6 0 neg 0 neg
7 100 neg 100 neg
8 100 neg 100 neg
9 400 pos 100 neg
10 400 pos 400 pos
11 400 pos 400 pos
12 400 pos 400 pos
13 1600 pos 1600 pos
14 400 pos 400 pos
21 1600 pos 1600 pos
28
Months
1600 pos 1600 pos
5 1600 pos 1600 pos
6 1600 pos 1600 pos
7 1600 pos 1600 pos
8 1600 pos 1600 pos
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Appendix M: IgG antibody titre to CCHF virus in relation to day post infection as detected by IgG
sandwich ELISA using sucrose acetone extracted and recombinant antigen in serum samples collected
from an experimentally infected sheep (number 48).
sucrose acetone antigen Recombinant antigen
Day IeG titre Interpretation IeG titre Interpretation
0 0 neg 0 neg
1 0 neg 0 neg
2 0 neg 0 neg
3 0 neg 0 neg
4 0 neg 0 neg
5 0 neg 0 neg
6 0 neg 0 neg
7 0 neg 0 neg
8 0 neg 0 neg
9 0 neg 0 neg
10 100 neg 100 neg
11 100 neg 100 neg
12 100 neg 100 neg
13 100 neg 100 neg
14 100 neg 100 neg
21 400 pos 100 neg
28 400 pos 100 neg
Months
5 400 pos 400 pos
6 400 pos 400 pos
7 0 neg 0 neg
8 1600 pos 1600 pos
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Appendix N: IgG antibody titre to CCHF virus in relation to day post infection as detected by IgG
sandwich ELISA using sucrose acetone extracted and recombinant antigen in serum samples collected
from an experimentally infected sheep (number 37).
sucrose acetone antigen Recombinant antigen
Day IgG titre Interpretation IgG titre Interpretation
0 0 neg 0 neg
1 0 neg 0 neg
2 0 neg 0 neg
3 0 neg 0 neg
4 0 neg 0 neg
5 100 neg 100 neg
6 400 pos 100 neg
7 400 pos 100 neg
8 400 pos 400 pos
9 400 pos 400 pos
10 1600 pos 400 pos
11 1600 pos 1600 pos
12 1600 pos 1600 pos
13 1600 pos 1600 pos
14 1600 pos 1600 pos
21 400 pos 1600 pos
28
Months
1600 pos 1600 pos
5 1600 pos 1600 pos
6 1600 pos 1600 pos
7 1600 neg 1600 pos
8 1600 pos 1600 pos
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